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The incidence of cancer is on the rise with a reported 1 in 3 people being directly affected by 
cancer. Cancer is the uncontrolled proliferation and atypical growth of cells. Symptoms of cancer 
may include general symptoms such as indigestion, anorexia, unexplained weight loss and pain. 
Chemotherapy, radiation, and surgery are used alone or in combination to reduce the tumour size 
and rate of growth, palliate symptoms or to remove the tumour. However, these treatments carry 
risks and often cause side effects such as fatigue, pain, nausea and vomiting, anorexia, alopecia, 
and blood disorders such as anaemia. Due to these symptoms and side-effects, patients often seek 
complementary medicine (CM) to alleviate the side-effects of these treatments. Cannabis and 
cannabinoids, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), are useful in the 
management of nausea, anorexia, and pain related to cancer and chemotherapy. However, the 
safety and potential adverse effects may lead to limitation in the use of cannabinoids. International 
studies have shown a high prevalence of CM usage in cancer patients. 
 
The aim of this study was to determine the knowledge and recommendation of cannabis and 
cannabinoids for cancer management by oncologists in South Africa by means of a questionnaire. 
 
The research sample consisted of 18 oncologists and radiology oncologists combined from a pool 
of 239 oncologists registered with the Health Professions Council of South Africa (HPCSA) as of 
2020. The researcher contacted participants via email or telephonically and provided them with 
the research study information letter (Appendix A) and the research consent form (Appendix B), 
along with an online link to, or physical copy of the survey (Appendix C). The questionnaire took 
10-15 minutes to complete and confidentiality was maintained throughout. Data from this survey 
was collected and documented by the researcher with the assistance of a statistician and analysed 
using frequencies and column table analysis. The questionnaire consisted of 6 sections. Each 
section explored a different aspect of oncologists’ understanding surrounding cannabis and 
cannabinoids in cancer management. 
 
In the study, the typical participant was male (66.7%) between the age of 30-39 (55.6%) and based 
in Gauteng (88.9%) with 10-19 years (50%) of experience in the field of oncology. Section B 
revealed that an almost even distribution (55.6%) of participants were in support of the therapeutic 
use of cannabis and cannabinoids. Furthermore, some participants perceived value in therapeutic 
use of cannabis and cannabinoids in cancer management (66.7%) and chemotherapy or radiation 
side-effects (61.1%). This section displays a positive response for the use of cannabis and 
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cannabinoids in conjunction with cancer treatments. Results from Section C showed more than 
half of the participants were aware that cannabis is currently legal in South Africa, including for 
therapeutic purposes (61.1%) and is considered legal only when used in the confines of one’s home 
(61.1%). However, when asked if they (participants) could apply to the Director General of Health 
to prescribe cannabis for therapeutic purposes to a patient, an even distribution responded as yes 
(33.3%), no (33.3%) and I do not know (33.3%). This section revealed gaps missing in oncologists’ 
knowledge of current legislation surrounding cannabis and cannabinoids. 
 
With regards to knowledge of cannabis and cannabinoids, 77.8% of participants were able to 
differentiate cannabis and cannabinoids as different substances, while fewer participants (55.6%) 
were familiar with international guidelines and a handful (22.2%) of participants were aware of 
the dependence forming potential of cannabis. Internet and websites (33.3%), journals (33.3%) 
and evidence-based research and clinical trials (22.2%) served as the primary sources used to 
obtain knowledge and information about cannabis and cannabinoids. This highlights that there 
may be a lack of knowledge regarding cannabis and cannabinoids or a bias in sources used. 
 
Participants were asked which symptoms they thought cannabinoids may relieve, of which pain 
(94.4%), anorexia (83.3%), nausea (77.8%), vomiting (55.6%) and insomnia (55.6%) were the 
most common responses. The use of cannabis was favoured in advanced stage cancers (44.4%) 
and palliative care (72.2%). There was strong support for the use of cannabis in carcinomas 
(88.9%), sarcomas (88.9%), leukaemia (61.1%), lymphomas (72.2%), myelomas (77.8%) and 
brain and spinal cord cancers (94.4%).  
 
Section F explored questions surrounding the prescription of cannabis by medical professionals. 
Almost all participants (94.4%) selected that practitioners should complete training before being 
able to prescribe cannabis which further verifies that there is a lack of knowledge and education 
within the field. However, data shows that HPCSA-registered oncologists (38.9%) and medical 
doctors (61.1%) should be able to prescribe medicinal cannabis. Oncologists’ support for 
practitioners registered with the Allied Health Professions Council of South Africa (AHPCSA) 
had less support, namely homeopaths (27.8%), and naturopaths (22.2%). The study found that a 
larger number of participants (61.1%) said that they did not currently recommend or prescribe 
cannabis or cannabinoids as an adjunct to cancer treatment. However, participants stated that they 
would prescribe cannabis to treat pain (100%), anorexia (88.9%), nausea (66.7%), insomnia 
(50%), cachexia (44.4%), general wellbeing (38.9%), vomiting (27.8%), depression (27.8%) and 
weakness (5.6%). The majority of the participants in this study remained neutral, allowing patients 
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to decide on the use of cannabis as an adjunct for themselves (61.1%). However, 38.9 % of 
participants initiated a conversation with only some of their patients, while over half (55.6%) the 
participants never initiated a conversation regarding cannabis use with their patients. 
 
Most participants (61.1%) indicated that they would recommend CBD rather than synthetic THC 
(22.2%), cannabis plant (11.1%), and other forms of cannabis. (16.7%). In administration forms, 
registered cannabis oil extracts were most preferred (55.6%). All participants (100%) responded 
that there was no current criterion or guideline they followed to determine their prescription of 
cannabinoids. Cannabis was perceived as effective by 22.2% of the participants, while just over 
half of the participants (55.6%) rated the efficacy as neutral. There was one participant (5.6%) who 
perceived cannabis as completely ineffective and 16.7% of participants stated that they did not 
know whether cannabis was effective or not. None of the participants responded that cannabis was 
very effective or ineffective. 
 
The outcomes of the study showed that there is a need for further education on cannabis in cancer 
management. Furthermore, oncologists had a positive perception regarding the use of cannabis 
and cannabinoids but would caution their patients based on dosage and guideline ambiguity. Better 
education would allow oncologists and medical professionals to better understand cannabis 
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CHAPTER ONE: INTRODUCTION 
 
1.1 Problem Statement 
The incidence of cancer is on the rise with a reported 1 in 3 people being directly affected by 
cancer. Cancer is the world’s second leading cause of death after cardiovascular diseases. Cancer 
is the uncontrolled proliferation and atypical growth of cells (WHO, 2018). Symptoms of cancer 
may include general symptoms such as indigestion, anorexia, unexplained weight loss and pain 
(WHO, 2019). Chemotherapy, radiation, and surgery are used alone, or in combination to reduce 
the tumour size and rate of growth, palliate symptoms or to remove the tumour. However, these 
treatments carry risks and often cause side-effects such as fatigue, pain, nausea and vomiting, 
anorexia, alopecia, and blood disorders such as anaemia (ACS, 2020b). Due to these symptoms 
and side-effects, patients often seek complementary medicine (CM) to alleviate the side effects of 
these treatments (Abrams, 2016). Cannabinoids are useful in the management of nausea, appetite 
suppression (anorexia) and pain related to cancer and chemotherapy. However, the safety and 
potential adverse effects may lead to limitation in the use of cannabinoids (ACS, 2020a). 
International studies have shown a high prevalence of CM usage in cancer patients; a high rate of 
non-disclosure of these medications to their oncologists and suggested that oncologists should 
study the CM modalities to better counsel their patients (Jou and Johnson, 2016). There is currently 
little research available in South Africa relating to oncologists’ knowledge and recommendation 
of cannabis and cannabinoids.  
 
This research was a quantitative-descriptive questionnaire survey design. The study was 
distributed physically and electronically to 80 oncologists registered in South Africa. Participation 
was voluntary and oncologists who met the inclusion criteria and consented to participation then 
completed the questionnaire. Participants that received the survey via email were provided with a 
link to the online survey and completed it in their own private setting. Participants that received 
the survey as a hardcopy received it in a sealed envelope at their practice. The questionnaire took 
approximately 10-15 minutes to complete and confidentiality was maintained throughout. Data 
from this survey was collected and documented by the researcher with the assistance of the 
statistician and analysed using frequencies and column table analysis. 
 
The outcome of the study showed that with regards to the recommendation and perceived value of 
cannabis and cannabinoids, most oncologists supported the use of cannabis and cannabinoids to 
ameliorate cancer symptoms and treatment side-effects. This study may provide the groundwork 
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The aim of this study was to determine the knowledge and recommendation of cannabis and 
cannabinoids for cancer management by oncologists in South Africa by means of a questionnaire. 
 
1.3 Benefits of the Study 
This study was the first of its kind amongst oncologists and within South Africa. It may encourage 
and promote further research into other aspects of cannabis and cannabinoids and cancer 
treatments. Furthermore, it may indicate the potential use of cannabis and cannabinoids as an 
alternative, or adjunct to allopathic cancer treatment.  This study may benefit oncologists, 
healthcare practitioners, patients, educators, and researchers. 
 
1.4 Assumptions of the Study 
 For the purpose of this study, it was assumed that: 
• Participants would answer the questionnaire truthfully and honestly without bias or prejudice; 
• The responses received would be a reflection of the medical oncology fraternity; and  
• The participants would form a cohesive group as their education and qualifications and 





CHAPTER TWO: LITERATURE REVIEW 
 
2.1 Introduction 
Cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million 
deaths in 2018. Globally, about 1 in 6 deaths is due to cancer (WHO, 2018). With 1 in 3 people 
being directly affected by cancer this disease is one of the world’s most pressing health concerns 
(NCI, 2018). There is an increase in the incidence of cancer with the number of new cases expected 
to rise by approximately 70% over the next twenty years (WHO, 2017). Many patients diagnosed 
with cancer will consult with, and are treated by an oncologist and may be required to undergo 
chemotherapy, radiation, or surgery. As a result of this, patients are subjected to the therapy’s 
unwanted side effects. Cannabis, which derives its action from cannabinoids and other compounds, 
is used by patients as an adjunct therapy to aid in the alleviation of these effects (Pergam et al., 
2017). This literature review aims to provide an overview of cancer, its staging, symptoms and the 
various forms of treatments and related side-effects. Furthermore, this literature review aims to 
understand the mechanism of action of cannabinoids and their role in reducing symptoms 
associated with cancer, as well as the legislation and medicinal use of cannabis.  
 
2.2 Cancer 
2.2.1 Aetiology of Cancer 
Cancer arises within the multistep process of the cell cycle in which there is a transformation of 
normal cells into cancer cells. The previously normal cells progress from a pre-cancerous lesion to a 
malignant tumour. These deviations are the result of the interaction between an individual's genetic 
factors and three categories of external factors. A carcinogen is any substance that is directly involved 
in the cause of cancer. These external factors include physical carcinogens, chemical carcinogens, 
and biological carcinogens (WHO, 2018). Physical carcinogens include asbestos fibres, corpuscular 
radiations, extremely low or high temperatures and some mechanical traumas, while chemical 
carcinogens include food colourants, additives, and preservatives. Biological carcinogens include 
steroid hormones, certain bacteria or virus strains and genetic factors which may accelerate an 
individual’s predisposition to cancer (Pambuk and Muhammad, 2018; WHO, 2018) 
 
The World Health Organization (WHO) attributes almost one third of cancer diagnoses to the five 
leading behavioural and dietary risks, namely high body mass index, low fruit and vegetable intake, 
lack of physical activity, tobacco use, and alcohol use (WHO, 2018). 
In 2012, approximately 15% of cancers diagnosed were ascribed to infections such as Helicobacter 
pylori, Human papillomavirus (HPV), Hepatitis B virus, Hepatitis C virus, and Epstein-Barr virus. 
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Hepatitis B and C are said to significantly increase the risk of hepatic cancer, while HPV and HIV 
increases the risk of cervical cancer (Plummer et al., 2016). 
 
2.2.3 Pathogenesis of Cancer 
Cancer is a disease process in which the body’s cells begin to rapidly divide to form an abnormal 
growth, typically referred to as a tumour. The growth may either be classified as a benign or malignant 
growth. Benign tumours are enclosed in a capsule. Therefore, they are not locally invasive and do not 
spread or metastasize. Tumours that are invasive have no capsule and spread into nearby tissues, 
metastasise, and are referred to as malignant cancer cells (Stylianopoulos et al., 2012). As these 
malignant tumours grow the cells may break off and travel to distant places in the body through the 
blood or the lymphatic system and form new tumours distant to the original tumour, this is referred 
to as metastases (NCI, 2018; WHO, 2018). It is proposed that six alterations in cell physiology result 
in malignant growth: 
1. Autonomy from growth signals; 
2. Adapting an insensitivity to growth inhibitory signals; 
3. Superseding programmed cell death (apoptosis); 
4. Unrestricted replication potential; 
5. Angiogenesis, which is the recruitment and proliferation of blood vessels; and 
6. Invasion and metastasis into surrounding and distant tissue (Cooper, 2019; Wilkinson et al., 
2015). 
 
It is thought that most cancers arise from a series of mutations rather than a single isolated mutation. 
This is represented in Figure 2.1 where the multistep carcinogenesis in the development of colorectal 





Figure 2.1: The multistep carcinogenesis in colorectal cancer (Wilkinson et al., 2015). 
 
2.2.4 Incidence of Cancer 
The most common cancers are lung and breast cancer, followed by colorectal, prostate, skin, and 
stomach cancer (WHO, 2018). Within South Africa, there are on average 115 000 individuals 
diagnosed with cancer per year with a cancer survival rate of 6/10. Since 2014, the National Cancer 
Registry (NCR) has yet to be updated (CANSA, 2019).   
 
 
Figure 2.2: Percentages of new cancer cases and cancer deaths worldwide in 2018 
(GLOBOCAN, 2018).  
6 
 
However, Discovery Health is one of South Africa’s leading medical aids, and in 2018 they reported 
that 38 295 Discovery Health Medical Scheme (DHMS) members actively received treatment for 
cancer, with the overall prevalence of cancer increasing by 45% since 2011. Discovery Health also 
reported 7 597 DHMS members had been newly diagnosed with cancer in 2018, with the incidence 
increasing by 10% since 2011 (Discovery, 2018).  
 
 
Figure 2.3: The top five most common histologically diagnosed cancers of men and women 
according to the National Cancer Registry (2014) (CANSA, 2019). 
 
The Cancer Association of South Africa (CANSA) lists the 5 most prevalent cancers in men as 
prostate, colorectal, lung, unknown origin and Kaposi sarcoma, while the five most predominant 
cancers in the female population are breast, cervical, unknown origin, colorectal and uterine. 
“Unknown origin” cancers refer to a diagnosis in which the cancer has spread throughout the body, 
where the original location of the growth cannot be determined. This may also be referred to as an 
“occult primary tumour”. Table 2.1 represents the top five most common histologically diagnosed 
cancers of men and women according to the National Cancer Registry (2014) (CANSA, 2019).  
 
2.2.5 Cancer Symptoms 
The signs and symptoms of cancer depend on the location, size, metastasis and staging of the 
malignancy. There are, however, general symptoms of a suspected malignancy which include: 
unexplained weight loss, fever, fatigue, pain and changes of the skin and hair (ACS, 2020b).  
The spectrum of symptoms related to cancer manifestation is extensive. Cancer Research UK 
(CRUK) provides key signs and symptoms of cancer, attributing early detection to more successful 




While symptoms are specific to the site of cancer, each type of cancer has a set of common 
symptoms which may prove useful in the early detection of cancer. These common symptoms are 
outlined by the WHO (WHO, 2019): 
 
Table 2. 1: The various symptoms of cancer relative to the location of the tumour (WHO, 
2019) 
Type of Cancer Common Symptoms  
Breast Breast lumps, skin or nipple retraction, discharge from the 
nipples (usually with blood), changes to the appearance and skin 
of the areola 
Cervical Bleeding after intercourse, excessive vaginal discharge 
Colon and Rectal Change in bowel habits, blood in stool, unexplained weight loss 
Cancers of the 
Alimentary Tract  
Leucoplakia, nodes in the upper neck, abdominal pain, weight 
loss, indigestion, hoarseness of voice 
Skin Lesions with irregular borders and growing lesions. 
Discoloration to the skin with itching or bleeding 
Prostate Difficulty in urination, increased frequency of nocturnal 
urination 
Testicular Asymmetrical testicular swelling and pain 
 
2.2.6 Cancer Staging 
Cancer staging is a system used to describe the extent to which the cancer has spread at the time 
of diagnosis. The staging of a tumour describes its size, evaluates lymph node involvement, and 
the presence or absence of metastases (ACS, 2016b).  
 
The TNM system was developed to standardize the diagnosis of cancers by using 3 categories to 
stage cancer, namely:  
1. The size of the Tumour and if it has spread to immediate areas (T); 
2. The involvement of Lymph nodes (N); and 
3. The presence or absence of Metastases (M) (AJCC, 2009; NCI, 2015). 
 
Furthermore, each cancer type has its own classification with additional values or subcategories. 
The basis for these classifications is detailed below (Wilkinson et al., 2015): 
• Tx – Primary tumour cannot be assessed  
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• T0 – No evidence of primary tumour 
• Tis – Carcinoma in situ 
• T1-4 – size and/or extent of tumour (with 1 denoting a small tumour with minimal invasion 
while 4 denotes a large tumour with extensive invasion) 
• Nx – Nodes cannot be assessed 
• N0 – No nodal involvement 
• N1-3 – Regional node metastases (with 1 denoting less than four regional lymph nodes 
involved while 3 denotes involvement in distant nodes.) 
• M0 – No distant spread 
• M1- Distant metastases (NCI, 2015; Wilkinson et al., 2015; WebMD, 2019b) 
 
Grading can be used in conjunction with cancer staging to assess the abnormality of the tumour 
cells in comparison to normal cells, and the histological appearance of the tumour cells. Grading 
tumours may assist doctors in interpreting the behaviour of a tumour, higher grade tumours grow 
more rapidly in comparison to low-grade tumours. The grading system is as follows:  
• Grade X: Grade cannot be assessed 
• Grade 1: Well differentiated 
• Grade 2: Moderately differentiated 
• Grade 3: Poorly differentiated 
• Grade 4: Undifferentiated (CRUK, 2014; NCI, 2013) 
 
“Differentiated” refers to cancer cells resembling normal tissue. “Poorly differentiated” and 
“undifferentiated” refers to cancer cells appearing abnormal. Normal structures and tissue patterns 
are also atypical (CRUK, 2014). The staging of the cancer typically determines the most 
appropriate and effective treatment as well as the prognosis of the patient (Wilkinson et al., 2015). 
 
2.2.7 Prognosis of Cancer 
Overall, more than 50% of individuals diagnosed with cancer may live for more than five years. 
There are, however, many cancers which have survival rates of more than 90%. An early diagnosis 
is essential to ensure treatment begins as soon as possible in order to achieve the best possible 
outcome. Some cancers may cause damage to essential organs, causing secondary diseases which 
may be the cause of death rather than the cancer itself. Table 2.2 depicts the five (5) types of 




Table 2. 2: Types of cancer and their respective 5- and 10-year survival rates (NCI, 2020). 
 
















Diffuse intrinsic pontine glioma (brain 
stem) 
<1% 0% 
Glioblastoma 3% - 42% 19% 
Pancreatic cancer (all types) 8.2% 2.2% 
Mesothelioma 9% 3% 











Breast cancer in situ  100% 100% 
Prostate cancer  98.6% 91% 
Thyroid cancer  98.2% 94.6% 
Testicular cancer  95.1% 87% 




2.3 Cancer Treatment- Oncology 
Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of 
cancer. Patients or physicians may choose to include other allopathic or complementary medicines 
into the treatment plan to treat the side-effects from the primary treatment or symptoms of the 
tumour itself (CRUK, 2018b).  
 
2.3.1 Oncologists 
An oncologist is a specialist doctor who treats cancer and provides medical care for a person 
diagnosed with cancer. Oncologists may choose to solely practice chemotherapy, radiation or 
surgery or may incorporate and recommend various treatment methods into their practice (ACS, 
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2018). Oncologists may recommend various treatment options to their patients. This includes 
chemotherapy, radiation and surgery or a combination of treatment options (CRUK, 2018b).   
 
There are currently 239 oncologists registered with the Health Professions Council of South Africa 
(HPCSA) (HPCSA, 2018).  To qualify as an oncologist in South Africa, a six-year degree, The 
Bachelor of Medicine & Bachelor of Surgery (MBBCh) is needed. Once qualified, doctors are 
required to do two years of internship and one year of community service before being permitted 
to pursue specialty training. Thereafter the doctor will complete a specialization in Internal 
Medicine before continuing onto a fellowship in oncology (The University of the Witwatersrand, 
2018) 
 
2.3.2 Chemotherapy  
Chemotherapy refers to the treatment of disease by use of chemical substances. It is particularly 
useful in cancer treatment by cytotoxic drugs and other drugs (Lexico Dictionaries | English, 
2020). Chemotherapy systemically targets rapidly dividing cells by disrupting the cell cycle to kill 
cancer cells (cytotoxic) and/or preventing cell division (cytostatic) in order to cure a specific 
cancer, shrink the tumour, kill metastases, or palliate symptoms such pain or pressure caused by 
the growth (CRUK, 2018a; ACS, 2016a).  Chemotherapy is administered via injection, intra-
arterially, intra-peritoneally, intravenously (using a port, pump, needle, or catheter), topically or 
orally (WebMD, 2019a). Chemotherapy may be given before surgery to shrink the tumour and 
increase the success rate (neoadjuvant), as an adjuvant therapy to decrease the chance of relapse 
after a surgery, as a primary therapy, or as palliative therapy to potentially prolong survival or 
provide a form of relief from symptomatic metastatic disease. Chemotherapy drugs may be given 
in combination or as single agents. It is thought that combined chemotherapy drugs improve the 
overall response of cytotoxicity by offering a broader range of drug activity against tumour cells 
(Mokhtari et al., 2017).  
 
Chemotherapy is generally administered in cycles, which is divided into a period of treatment and 
a rest period. During the rest period, the body is given time to recover and make new, healthy cells 
before beginning the next cycle of treatment (WebMD, 2019a; MedlinePlus, 2020).  
 
There are six types of chemotherapy: 




• Plant alkaloids are derived from plants and are cell-cycle specific thus targeting the cell during 
various stages of division.  
• Anti-tumour antibiotics are produced by fungi from the species Streptomyces. These act at 
multiple stages of the cell cycle and are therefore cell-cycle specific. 
• Anti-metabolites can be compared to substances found within a normal cell. When a cell makes 
use of these substances during metabolism, the cell is unable to divide. These are cell-cycle 
specific.  
• Topoisomerase inhibitors are drugs which interfere with the action of topoisomerase enzymes 
within the cell which, control and manipulate the structure of DNA required for replication. 
• Miscellaneous anti-neoplastic agents are unique in their actions and used for specific natures of 
cancer.  (Chemocare, 2017; Alto and Bay, 2020). 
 
 
2.3.2.1 Chemotherapy Side Effects 
While chemotherapy seeks to destroy unhealthy cancer cells, it simultaneously affects healthy, 
rapidly growing cells like those of the hair, skin, intestines, and bone marrow, thus causing side 
effects. These side effects include, but are not limited to, fatigue, pain, nausea and vomiting, mouth 
sores, anorexia, constipation or diarrhea, alopecia, skin and nail abnormalities, bone loss, 
peripheral neuropathy and kidney damage (ASCO, 2017). Hormonal imbalances due to 
chemotherapy may lead to menstrual changes, infertility, and early onset menopause in women, 
while some men may suffer from low libido and a low sperm count. Chemotherapy also affects 
the bone marrow and production of blood cells. A decrease in white blood cells makes the patient 
more susceptible to infection while decreased platelets are responsible for easy bruising in patients. 
A decreased red blood cell count may indicate anaemia and subsequent symptoms such as fatigue 
(ACS, 2020b).  
 
2.3.3 Radiation and Radiation Side Effects 
Radiation therapy uses ionizing radiation to produce free radicals which damages DNA and thus 
kills tumour cells. Normal cells are better able to repair this damage than cancer cells, and thus 
can restore themselves before the next dose or radiation is administered (Wilkinson et al., 2015).  
Radiation therapy may also be used as a precautionary measure before and after surgery. It has 
been found to significantly reduce the recurrence of local tumours and increase survival rates 




Side effects of radiation are similar to those of chemotherapy, including fatigue, alopecia, nausea 
and vomiting, damage to skin and mucous membranes, leukopenia, and thrombocytopenia (ACS, 
2015; NCI, 2018). 
 
2.3.4 Surgery and Associated Risks 
Surgery is often used in conjunction with other types of cancer treatment. Surgery types include 
curative, preventative, diagnostic or staging, palliative or supportive. These surgeries aim to: 
diagnose the type and extent of cancer via tissues used for histological diagnosis and staging, 
remove the tumour, prevent precancerous growth, and alleviate symptoms caused by the tumour 
or as a prophylactic treatment where patients carry high-risk cancer genes, such as the BRCA or 
FAP gene (Wilkinson et al., 2015). Surgery may provide the best prognosis for cure, especially 
where the growth has not metastasized. Some common types of surgery include, cryosurgery, laser 
surgery, electrosurgery, Mohs surgery and laparoscopic surgery. (Mayo Clinic, 2020). 
 
A surgeon may perform a laparoscopic procedure to see inside the body cavity without making 
large incisions. Instead, several small incisions are made, and a tiny camera and surgical tools are 
inserted into the body. This allows for faster recovery and a reduced risk of complications. 
Laparoscopic surgery is used in cancer diagnosis, staging, treatment and for symptom relief (Mayo 
Clinic, 2020). 
 
An operation in which the surgeon cuts into the body to operate is referred to as an invasive 
surgery. The possible risks associated with surgery include organ damage, blood loss, reactions to 
anesthesia, pain and discomfort, and infections (Stanford Healthcare, 2018). Surgeons seek the 
least invasive route in which maximal healthy tissue and organ function can be preserved. This 
allows for better healing post-operatively (ACS, 2014).  
 
 
2.4 The Human Endocannabinoid System 
Human beings produce cannabinoids internally through an important system in our bodies called 
the endocannabinoid system (ECS). The ECS is a biological system composed of 
endocannabinoids, which are endogenous neurotransmitters that bind to cannabinoid receptors, 
and cannabinoid receptor proteins that are expressed throughout the vertebrate central nervous 




2.4.1 Endocannabinoids and CB1 and CB2 Receptors 
Anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) are the two endocannabinoids produced 
in the body (Grotenhermen and Müller-Vahl, 2012).  Developing research suggests that the ECS 
may be involved in regulating physiological and cognitive processes, including fertility, 
pregnancy, during pre- and postnatal development, appetite, pain-sensation, mood, and memory, 
and in mediating the pharmacological effects of cannabis  (Donvito et al., 2017; Fride, 2004).  
 
The endocannabinoid system is a constellation of cannabinoid receptor type 1 (CB1) and 
cannabinoid receptor type 2 (CB2) receptors, as well as endogenous cannabinoid receptor agonists.  
The cannabinoid receptors CB1 and CB2 respond to a ligand binding to its receptor. These ligands 
may be endogenous (AEA and 2-AG), as produced by the mammillary bodies, or exogenous such 
as synthetic cannabinoids and plant-based cannabinoids from the cannabis plant (Mackie, 2008).  
 
 CB1 receptors can be found in the central nervous system (brain and spinal cord) as well as in 
peripheral organs and tissues, while CB2 receptors are expressed predominantly by cells of the 
immune system (Kendall and Yudowski, 2017). CB2 receptors are mainly found on white blood 
cells, the tonsils and spleen, and play a role in immunity (Turu and Hunyady, 2017). 
 
CB1 receptors have also been found not only in the central nervous system (CNS), but also in many 
peripheral organs and tissues, such as the immune cells, spleen, adrenals, sympathetic ganglia, 
pancreas, skin, heart, blood vessels, lung, and parts of the urogenital tract and gastrointestinal tract 
(Grotenhermen and Müller-Vahl, 2012). 
 
Typically, AEA and its mimetic phytocannabinoid THC, have a high affinity as  partial agonists 
of the CB1 receptor. 2-AG, along with its own mimetic phytocannabinoid, CBD  act as full agonists 
on both CB1 and CB2 receptors, but with a low-to-medium affinity for both endocannabinoid 
system receptors (Zou and Kumar, 2018). 
 
Both, AEA and 2-AG are produced on demand in response to an increased concentration of 
intercellular calcium. AEA and 2-AG are synthesized, transported, and inactivated differently in 





Figure 2.4: The endocannabinoid system in relation to other body systems (Elite Healthcare, 
2020) 
 
2.4.2 Physiological Actions of Endocannabinoids 
CB1 receptor activation leads to retrograde inhibition of the neuronal release of acetylcholine, 
dopamine, GABA, histamine, serotonin, glutamate, cholecystokinin, D-aspartate, glycine, and 
noradrenaline. The CB1 receptor is the most widely distributed G-protein-coupled receptor in the 
CNS. These complex interactions explain the large number of physiological actions of 
cannabinoids (Grotenhermen and Müller-Vahl, 2012).  
 
The endocannabinoid system of the body plays an integral role in the mediation of appetite, pain, 
mood and memory. CB1 receptors decrease pain and nausea in response to the body’s production 
of endocannabinoid ligands. CB1 receptor activation results in psychotropic effects, however, this 
does not occur when CB2 receptors are activated (Turu and Hunyady, 2017). 
 
2.5 Cannabis 
Cannabis, also known marijuana amongst other colloquial names, is a genus of the Cannabaceae 
family. Cannabis is further divided into three subspecies: Cannabis sativa, Cannabis indica and 
Cannabis ruderalis (USDA, 2018). Cannabis sativa grows as a tall plant with thin, light green 
leaves and has a longer flowering cycle than Cannabis indica, which is shorter in stature with 




Figure 2.5: Subspecies of Cannabis include C. sativa sativa, C. sativa indica, and C. sativa 
ruderalis (Hartsel et al., 2016). 
 
While there are many active constituents in the cannabis plant, the flowers of the female plant 
produce cannabinoids in the highest and most concentrated amounts, and they are therefore used 
for both medicinal and recreational use (Small, 2015). The Cannabis sativa plant is strongly 
influenced by environmental factors which will affect its growth habits. It is cultivated in 
numerous countries around the world for its medicinal, recreational, and industrial uses (Clarke 
and Merlin, 2013; Makgakga, 2004).  
 
2.5.1 Use of Cannabis 
Cannabis can be used by smoking, vaporizing, within food, or as an extract. Cannabis 
has psychological and physical effects, such as creating a "high" or "stoned" feeling, a 
general change in perception, heightened mood, and an increase in appetite. The onset may be felt 
within minutes when smoked, and within 30 to 60 minutes when cooked and eaten. Usually, the 
effects of cannabis consumption last for two to six hours (National Institute on Drug Abuse, 2019).  
 
The short-term side effects include, but are not limited to: a decrease in short-term memory, dry 
mouth, impaired motor skills, red eyes, and feelings of paranoia or anxiety. Long-term side effects 
may include addiction, decreased mental ability (where the onset of consumption was at a young 
age), and behavioural problems in children whose mothers used cannabis during pregnancy 
(MedlinePlus, 2018). However, the risk of developing addiction or dependency to cannabis is 
relatively low. Individuals who begin using marijuana before the age of 18, and individuals with 
a genetic predisposition to addiction are most at risk. Research suggests that between 9-30% of 
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those who use cannabis may develop some degree of dependency or addiction (NIH, 2020). There 
is a strong relation between cannabis use and the risk of psychosis, though the cause-and-effect 
remains a contested matter (Leweke et al., 2016). However, THC compounds in cannabis are 
responsible for its psychogenic effects whereas CBD may provide a buffering effect to the 
potentially psychosis-inducing effects of THC or may be used as an isolated compound to treat 
psychosis  (Sarris and Firth, 2018).  
 
Cannabis may be used recreationally, medicinally or for spiritual purposes.  Recreationally, 
cannabis is often used for its psychoactive properties which includes the feeling of relaxation and 
euphoria, altered consciousness, and increased sensory perception (Burdette et al., 2018).  
 
Cannabis used for medicinal purposes may be referred to as medical marijuana and developing 
research suggests it may be useful in the following conditions: Alzheimer's disease, cancer, 
Crohn's disease, anorexia, epilepsy, posttraumatic stress disorder (PTSD), multiple sclerosis, 
nausea and pain (Leafly, 2014).  Cannabis has also been found to benefit neurological conditions 
such as: malignant brain tumours, Parkinson's disease, neuropathic pain, and the childhood seizure 
disorders Lennox-Gastaut and Dravet syndromes. In addition, psychiatric and mood disorders, 
such as schizophrenia, anxiety, depression, addiction, post-concussion syndrome, and 
posttraumatic stress disorders are being studied using phytocannabinoids (Maroon and Bost, 
2018). The spiritual use dates back to 1400 BCE in the Indian subcontinent (Courtwright, 2001).  
 
2.5.2 Constituents of the Cannabis Plant  
The cannabis plant has both cannabinoid and non-cannabinoid type constituents. There are 113 
known types of cannabinoid constituents which exhibit different effects on the body (Aizpurua-
Olaizola et al., 2016).  
 
Non-cannabinoid type constituents include terpenes, hydrocarbons, nitrogen-containing 
compounds, carbohydrates, flavonoids, fatty acids, and phenols. These non-cannabinoid 
constituents determine the taste, smell, metabolism, pigmentation, chemical structure, and 
synthesis of the plant (Andre et al., 2016). 
 
The terms cannabinoids and phytocannabinoids represent C21 terpenophenolic compounds found 





Both cannabis plants and people have chemical compounds in our systems called cannabinoids. 
As mentioned above, in the human body cannabinoids are called endocannabinoids, namely 
anandamide (AEA) and 2-arachidonoylglycerol (2-AG). When derived from the cannabis plant, 
they are called phytocannabinoids (OCS, 2019). The Cannabis sativa plant yields several 
cannabinoids (Figure 2.6), of which tetrahydrocannabinol (THC), cannabidiol (CBD) and 
cannabinol (CBN) are the most widely researched and used (Chandra et al., 2017). Cannabis sativa 
typically has high levels of THC and low levels of CBD, while Cannabis indica has moderate 
levels of THC and higher levels of CBD (Hartsel et al., 2016; Rahn, 2018).  The molecular 








Other cannabinoids include tetrahydrocannabivarin (THCV) which is a cannabinoid being 
researched for its use in metabolic conditions, diabetes, and weight loss (Wargent et al., 2013). 
Figure 2.7 shows the respective benefits and therapeutic uses (Leafly, 2014). 
 
 
Figure 2.7: Various diseases and therapeutic cannabinoid suggested (Leafly, 2014). 
  
In the 1920s, researchers began to study and isolate cannabinoids. CBD was isolated in 1963 by 
Mechoulam and Shvo who were able to represent the full structure of the CBD compound. Gaoni 
and Mechoulam then went on to isolated and describe THC in 1964. It is now the most well-known 
and most researched cannabinoid. Of the 113 cannabinoids that have been identified, none possess 




2.5.2.2 Tetrahydrocannabinol (THC) 
Tetrahydrocannabinol (THC) is the primary psychoactive component of the Cannabis plant. It has 
the chemical name Δ9-tetrahydrocannabinol (Figure 2.8). THC mimics the endocannabinoids AEA 
and 2-AG, and therefore acts on the CB1 and CB2 receptors (Guzmán et al., 2016).  THC binds to 
the CB1 cannabinoid receptors of the brain, producing effects such as euphoria, increased anxiety, 
delusions, and appetite stimulation (Howlett et al., 2010).  A 2013 study by Cridge and Rosengren 
reported that THC increased proliferation in specific cancer cell types such as lung and liver 
carcinomas however, the study found that THC has been found to decrease proliferation in certain 
breast cancer cell lines and at certain concentrations (Cridge and Rosengren, 2013). When used in 
combination with CBD, THC seems to have an enhanced anticancer effect when treating certain 
cancers; and less THC or lower doses of THC are needed to exhibit the same anticancer activity 










Figure 2.8: Chemical structure of Δ9-tetrahydrocannabinol (THC) (Cinquina et al., 2012) 
 
2.5.2.3 Cannabidiol (CBD) 
Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. Cannabidiol is a 
non-psychoactive cannabinoid and is the most abundant cannabinoid after THC (McAllister et al., 
2015). Unlike THC, CBD has a very low affinity for CB1 receptors, instead, it acts as a partial 
agonist at the CB1 receptors, but has a higher affinity to CB2 receptors but to a lesser extent than 
THC (Mahadevan et al., 2000).  
 
CBD does not affect consciousness or cause the sensation of getting “high”. This quality makes 
CBD an appealing option for those who are looking for relief from pain and other symptoms 




Studies have shown that CBD may help reduce chronic pain by impacting endocannabinoid 
receptor activity, reducing inflammation, and interacting with neurotransmitters. CBD may also 
help reduce chemotherapy-induced nausea and vomiting, which are among the most common 
chemotherapy-related side effects for those with cancer (Kubala, 2018; Darkovska-Serafimovska 
et al., 2018). There is also evidence which points toward a calming effect for CBD in the central 
nervous system (Shannon, 2019). The benefits of CBD extend into the treatment of acne, arthritis, 
heart disease, epilepsy, diabetes and more. However, side-effects of CBD include diarrhoea, 














Terpenes are fragrant oils found in many types of plants that produce a unique taste and smell. The 
characteristic scent of cannabis is from terpenes in the plant. Although cannabis characteristically 
has a musky aroma, each cannabis strain will have its own scent which is based on the number and 
type of terpenes present and which are dominant. Terpene scents can include spicy, peppery, floral, 
and fruity tones. Linalool, a common terpene found in lavender, may be associated with relaxation, 
and may enhance the psycho-active effect of cannabis. The concept of the entourage effect was 
first dubbed by Drs. Mechoulam and Ben-Shabat referring to the possibility that cannabinoids and 
terpenes work together in the overall effect of cannabis (Grotenhermen and Müller-Vahl, 2012; 
OCS, 2019). 
The five most common terpenes found in cannabis are myrcene, pinene, limonene, linalool and 
beta-caryophyllene (OCS, 2019) 
 
Figure 2.9: Chemical structure of cannabidiol (Cinquina et al., 2012) 
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2.6 Cannabis and Cannabinoids in Cancer 
Against the globally rising incidence of cancer and its significant association with mortality, 
morbidity and economic cost, the need for effective and alternative measures to manage the 
manifestations of cancer and treatment-related symptoms remains a priority (WHO, 2017). 
 
 Medical cannabis refers to the use of cannabis or cannabinoids as medical therapy to treat disease 
or alleviate symptoms. Cannabis and cannabinoids can be administered orally, sublingually, or 
topically. In addition, they can be smoked, inhaled, mixed with food, or made into tea. They can 
be taken in herbal form, extracted naturally from the plant, gained by isomerization of cannabidiol, 
or manufactured synthetically (Hazekamp et al., 2013).  
 
Cannabis preparations yield numerous therapeutic effects. It is used to treat a wide range of 
medical conditions including epilepsy, cancer, and inflammation (Borgelt et al., 2013). It is well 
known for its anti-tumour properties with specific success in breast, lung, colon, and prostate 
cancers (Shrivastava et al., 2011). In a study conducted in animal models, CBD has been shown 
to inhibit the progression of many types of cancer including glioblastoma, breast, lung, prostate 
and colon cancer (McAllister et al., 2015).Cannabis has antispastic, analgesic, antiemetic, 
neuroprotective, and anti-inflammatory actions which prove extremely useful in cancer treatment 
(Grotenhermen and Müller-Vahl, 2012). 
 
Typically, patients may use CBD to help treat inflammatory bowel disease, seizures, depression, 
diseases related to inflammation, psychosis or mental disorders and migraines. While THC has 
potential uses in treating glaucoma, muscle spasticity, low appetite and insomnia. Often CBD, 
THC or a mixed extract is used to treat symptoms of pain, anxiety and nausea (Fletcher, 2020).  
 
In placebo-controlled studies, inhaled cannabinoids were found to increase food intake and 
appetite. Anorexia is a widely acknowledged side effect of cancer as well as its treatment. In 
another study, synthetic THC was found to improve taste sensation.  Dronabinol, the first approved 
and licensed cannabinoid, was found to improve appetite in 64% of patients and 73% reported an 
improved taste sensation (Nelson, 2018; Abrams, 2013). The National Comprehensive Cancer 
Network Guidelines suggest cannabinoids as groundbreaking treatment for chemotherapy induced 
nausea and vomiting (NCI, 2017). Musty and Rossi (2001) reported that 80% of patients in their 
study found inhaled and oral cannabinoid derivatives had very effective reduction in 
chemotherapy-induced nausea and vomiting which was refractory to other anti-emetics. The use 
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of some cannabinoids as an anti-emetic is limited by the side effects of euphoria, depression, 
dysphoria, sedation, paranoia, and hyper-attention (Tramer, 2001). 
 
A study looked at the effects of CBD and THC in 177 people with cancer-related pain who did not 
experience relief from pain medication. Those treated with an extract containing both compounds 
experienced a significant reduction in pain compared to those who received only THC extract. The 
study concludes that THC: CBD extract is efficacious for relief of pain in patients with advanced 
cancer pain not fully relieved by strong opioids (Johnson et al., 2010; Kubala, 2018). 
 
In 2019, Dariš et al. reviewed the literature on anticancer effects of plant-derived and synthetic 
cannabinoids, to better understand their mechanisms of action and role in cancer treatment. The 
study deems cannabinoids as complex compounds that have a promising therapeutic potential for 
the treatment of variety of diseases, including cancer. More specifically, in vitro, and in 
vivo cancer models showed that cannabinoids can effectively modulate tumour growth, however, 
the antitumour effects appear to be largely dependent on cancer type and drug dose/concentration.   
 
2.7 Legislation of Cannabis in South Africa 
In 2019, the Western Cape High Court called for legislative changes to be made to the Medicines 
and Related Substances Control Act in order to make provision for the use of cannabis. The use of 
cannabis for medical purposes has been hypothesized to date back to at least 507 BC (Abrams, 
2013). The legality of cannabis for medical use varies by country, in terms of its possession, 
distribution and prescription as well as which medical conditions it can be used for (Medrano, 
2019). 
 
Countries that have legalized the medical use of cannabis includes, but are not limited to Germany, 
Norway, Netherlands, and New Zealand. In the United States of America, cannabis for medicinal 
use is legalized in 33 States but remains illegal at a federal level (NCSL, 2019). In South Africa 
there are currently no cannabis products that have been approved by the South African Health 
Products Regulatory Authority (SAHPRA), previously the Medicines Control Council (MCC) 
(SAHPRA, 2020).  
 
Under the Medicines Act, and in line with the Single Convention, cultivation, production, 
manufacture and use of medicinal cannabis products may only occur through a licence issued by 




Consumer and patient access to medicines and scheduled substances in South Africa is dependent 
on the schedule of the substance. Cannabis is a prohibited substance listed under Schedule 7 of the 
Schedules to the Medicines Act. However, medicines which have been registered by the SAHPRA 
containing cannabis, cannabis extracts, and cannabis-derived substances such as cannabinoids 
which are intended for therapeutic use, may be rescheduled and listed in Schedule 6 to align these 
products with the scheduling status of other restricted medicines. This measure allows patients to 
access medicinal cannabis products by means of a prescription issued by a medical practitioner 
where the product may be dispensed at pharmacy level. Cannabis products that are not registered 
by the SAHPRA will remain in Schedule 7 (SAHPRA, 2020). 
 
2.8 Scheduling of Cannabis 
Currently, cannabis is still listed as a Schedule 7 substance. Medical practitioners in South Africa 
can legally prescribe medicinal cannabis products with approval from the Department of Health 
(DOH) and the South African Health Products Regulatory Authority (SAHPRA) via the Section 
21 application route.  Medicinal cannabis is lawful when the cultivation, manufacture, prescribing, 
and supply complies with the guidelines set out by the SAHPRA as instructed by the DOH 
(Medical Cannabis, 2018).  
 
 
The scheduling of cannabis is as follows:  
“…Cannabis (the whole plant or parts or products thereof) and THC are currently listed 
as Schedule 7 substances in terms of the Medicines and Related Substances Act, 1965 (Act 
101 of 1965) (the Medicines Act), except when present in processed hemp fibre and 
products thereof, in a form not suitable for ingestion, smoking or inhaling purposes, and 
containing not more than 0,1 % THC; or when present in processed products from 
cannabis seed containing not more than 0.001 % THC; or when separately specified in 
Schedule 6 for therapeutic use. Synthetic cannabinoid substances are also listed separately 
in Schedule 7. THC (also known as the synthetic variant, dronabinol) is listed in Schedule 
6, when intended for therapeutic purposes. CBD is listed as a Schedule 4 substance. 
Certain CBD preparations have been excluded from the operation of the Schedules by the 
Minister of Health for a time-limited period, as per an exclusion notice (R.756) published 
in Government Gazette No.42477 on 23 May 2019. This does not infer that CBD is 
excluded from other requirements of the Act. Schedule 7 substances are deemed to have no 
legitimate medicinal use and can only be accessed by means of a permit issued by the 
Director General of the National Department of Health (NDoH). Medicines and 
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substances categorised as Schedule 4 or Schedule 6 are only available on the prescription 
of an authorised prescriber and can only be obtained from a pharmacy or the holder of a 
dispensing licence issued in terms of the Medicines Act…” (SAHPRA, 2020). 
 
2.9 Synthetic Cannabinoid Products 
Currently available, researched exogenous cannabinoids include synthetic cannabinoids, 
Dronabinol (trade name Marinol) and nabilone, (trade name Cesamet) and a standardised oil 
extract of the cannabis plant called nabiximols which is available under the trade name Sativex. 
Sativex contains both THC and CBD together with other naturally occurring phytochemicals 
(Porter, 2017).  The same company that produce Sativex produce another standardised oil extract 
of the cannabis plant called Epidiolex that has been registered with the US Food and Drug 
Administration.  Epidolex contains only CBD and no THC together with other naturally occurring 
phytochemicals.  Significant research around Dronabinol exists and as such it has been 
acknowledged by the US Food and Drug Administration for the management of anorexia, weight 
loss and nausea related to cancer and its therapy (USFDA, 2018).   
 
2.10 Cannabis and Complementary Medicine 
Complementary medicine (CM) covers a variety of therapies, botanicals, and dietary supplements. 
Complementary medicine is treatment that is used as an adjunct to standard treatment while 
alternative medicine is treatment that is used in place of conventional medicine (CRUK, 2018b).  
 
The use of cannabis is an integral part of the traditional armamentarium of various CM modalities 
and various preparations may be used for medicinal purposes as treatment within the scope of 
Homeopathy, Naturopathy, and other allied health professions (AHPCSA, 2017). 
 
In their 2016 study consisting of 17639 participants, Judson et al., found that there was a high 
percentage of patients using CM while undergoing treatment at a cancer centre in America. 
 
Arslan and Guler (2016) found that 60% of the 289 participants surveyed in America used CM as 
well as their conventional treatment, while nearly half the participants did not inform their 
clinicians about their alternative therapies. Participants of the study were all chemotherapy-
receiving cancer patients. 
 
Within the field of homeopathy, cannabis has been used in potentized, diluted form and tincture 
form since 1830. Samuel Hahnemann, the founder of Homeopathy, wrote about the use of both 
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Cannabis sativa and Cannabis indica in his book, Materia Medica Pura. He writes, “for a long 
time I employed the undiluted alcoholic tincture of cannabis, in the dose of the smallest portion of 
a drop.” (Hahnemann, 2002). William Boericke, an American homeopath wrote in the ninth 
edition of his book The New Manual of Homeopathic Materia Medica, published in 1927 that both 
Cannabis indica and Cannabis sativa should be dosed as a tincture. Cannabis indica was advised 
to be used in tincture and low attenuations while Cannabis sativa was advised to be dosed in 
tincture to the third attenuation (Boericke, 2007).  
 
2.11 Related Research 
There is limited evidence-based research available regarding oncologist’s perceptions and use of 
cannabis and cannabinoids in the treatment of cancer and chemotherapy symptoms and research 
studies have produced conflicting results (Bar-Sela et al., 2013).  
 
A survey of 141 practicing oncologists in Washington, D.C., by Schwartz and Beveridge (1994) 
revealed that various forms of cannabis were less preferred in the treatment of mild to moderate 
nausea and vomiting, and rather for the treatment of more severe symptoms induced by 
chemotherapy. The survey concluded that oncologists found cannabis in any form to be efficacious 
for 50% of patients with pre- or post-chemotherapy nausea or vomiting. However, one in four 
patients who received it complained of bothersome adverse effects. 
 
However, Charuvastra et al. (2005) conducted a survey from a group of 960 specialists throughout 
the United States of America to determine their support for ‘marijuana as a medical therapy’. The 
sample group consisted of family physicians, general internists, obstetrician-gynaecologists, 
psychiatrists, and addiction specialists. The research concluded that 36% of participants supported 
the legislation of medical marijuana, while 26% were neutral to the legalisation.  
 
In 2013, Adler and Colbert conducted an online poll to determine whether clinicians support the 
use of medical marijuana for cancer symptoms. Data was collected from 72 countries with a total 
of 1446 votes. The results showed 76% of votes in favour of the use for medical marijuana. 
 
In 2017, Pergam et al. surveyed 926 patients to determine their usage, dosage, and administration 
of cannabis, as well as their type of cancer and their current knowledge or education on cannabis. 
The study found that 66% of participants used cannabis during their treatment and 74% of the 




Stojanovic et al. (2017) surveyed pharmacy students to ascertain their knowledge and attitudes on 
the use of cannabis and its derivatives for medicinal purposes.  Of the participants surveyed, 91.2% 
agreed that there are therapeutic benefits to cannabis and its derivatives, but only 51.3% were 
familiar with the specific therapeutic effects.   
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CHAPTER THREE: METHODOLOGY 
 
3.1 Research Sample 
The research sample consisted of 18 oncologists and radiology oncologists combined from a pool 
of 239 oncologists registered with the AHPCSA as of 2020. The researcher contacted participants 
via email or telephonically and provided them with the research study information letter (Appendix 
A) and the research consent form (Appendix B) along with an online link to, or a physical copy of 
the survey.  
 
3.1.1 Inclusion Criteria 
Participants were included in the study if they were: 
• Registered with HPCSA as an Oncologist / Radiation Oncologist, and 
• Practicing in South Africa 
 
3.1.2 Exclusion Criteria 
Participants were excluded from the study if they: 
• Had already completed the questionnaire electronically via the email link. 
 
3.2 Research Design and Procedure 
The research involved a quantitative-descriptive survey that was implemented via email and 
completed digitally, or by visiting oncology practices and completing a hard copy version of all 
documents and the questionnaire. Relevant permission was obtained on approval from the Higher 
Degrees Committee (HDC) (Appendix D) and the Research Ethics Committee (REC) (Appendix 
E).  
 
Email participants followed an attachment to an information document explaining the purpose and 
procedures of the study (Appendix A) and were asked to mark a tick box giving their consent prior 
to filling in the questionnaire online (Appendix B).  
 
Participants that received the survey as a physical copy were provided with the same information 
letter (Appendix A), consent form (Appendix B) and the questionnaire (Appendix C) that all had 




Participation was voluntary and in a personal capacity, and participants could withdraw at any 
time. Participants that received the questionnaire via email received a link to the online 
questionnaire and completed it in their own private setting, while the participants that were visited 
in their practices could complete it in the privacy of their consultation rooms. The questionnaire 
took approximately 10-15 minutes to complete. Once completed and submitted, the form did not 
contain any identifying data, thus providing complete anonymity. The hard copy questionnaires 
were kept in a secure location, and all data was stored on a password protected laptop which could 
only be accessed by the researcher. 
 
3.3 Reliability and Validity Measures 
The questionnaire used in this study (Appendix C) was developed by the researcher after reviewing 
several studies including Stojanovic et al., (2017) and Pergam et al. (2017) and has been tailored 
to a South African context. The survey questionnaire was tested by a pilot study with a small 
sample group, no changes were made as the questions were deemed suitable and expansive 
enough. The results of the pilot study were not analysed or included in the research study. The 
purpose of the pilot study was to test the feasibility of the study and ensure that there was no 
ambiguity in the questions of the survey (Leon et al., 2011).  
 
3.4 Data Collection and Analysis 
Data from the questionnaires was captured by the researcher. The data obtained throughout this 
study were statistically analysed with the assistance of Statkon, UJ by using frequencies and 






CHAPTER FOUR: RESULTS 
 
4.1 Introduction 
The aim of this study was to determine the knowledge about and recommendation of cannabis and 
cannabinoids for cancer management by oncologists in South Africa by means of a questionnaire 
(Appendix C). A total of 60 surveys were distributed electronically via email, and physically by 
visiting practices in Johannesburg, Durban and Cape Town, and a total of 18 questionnaires were 
returned. The questionnaires were conducted from June 2019 until June 2020. 
 
The questionnaire consisted of 6 Sections that each explored a different aspect of oncologists’ 
understanding surrounding cannabis and cannabinoids in cancer management. The questionnaire 
was made up of the following Sections: Section A – demographic and work experience data; 
Section B – use and perceived benefits of cannabis and cannabinoids; Section C – knowledge 
regarding the legalization of cannabis; Section D – broad-based questions on cannabis and 
cannabinoids and the sources used to obtain information on them; Section E – recommendation 
and perceived value of cannabis and cannabinoids; and Section F – the prescription of cannabis 




As seen in Figure 4.1, 55.6% (n=10) of participants were age 30-39, while 27.8% (n=5) were age 
40-49, a further 11.1% (n=2) were aged 50-59 and 5.6% (n=1) were aged 60 years and over.  
 
 


































Figure 4.2 shows the gender distribution of the participants. The majority of participants 66.7% 




Figure 4.2: Gender 
 
4.2.3 Province 
As depicted in Figure 4.3, the bulk of the participants (88.9%, n=16) practice within Gauteng, and 
the remaining participants (11.1%, n=2) practice in Kwa-Zulu Natal.  
 
 
Figure 4.3: Province 
 
4.2.4 Years of Experience 
Participants were asked to indicate their number of years of experience in oncology. Figure 4.4 
displays the varying distribution of data in which 33.3% (n=6) of participants had 0-5 years of 
experience in oncology, while 11.1% (n=2) of participants had 6-9 years of experience. Half of 
the participants (50%, n=9) had 10-19 years of experience, and the remaining 5.6% (n=1) had 20-






















































Figure 4.4: Years of Experience 
 
4.3 Perception on the Use of Cannabis and Cannabinoids 
 
4.3.1 Support of the Therapeutic / Medicinal Use of Cannabis and Cannabinoids 
Participants were asked whether they currently support the therapeutic / medicinal use of cannabis 
and cannabinoids. There was an almost even response from participants, where 55.6% (n=10) 
supported the therapeutic / medicinal use of cannabis and cannabinoids while 44.4% (n=8) of 




Figure 4.5: Support of the Therapeutic / Medicinal Use of Cannabis and Cannabinoids 
 
4.3.2 Perceived Value in the Therapeutic / Medicinal use of Cannabis and Cannabinoids in 
Cancer Management 
Participants were asked if they saw value in the therapeutic / medicinal use of cannabis and 
cannabinoids in cancer management. Overall, 66.7% of the participants (n=12) found value in the 
therapeutic / medicinal use of cannabis and cannabinoids in cancer management, while 22.2% of 
them (n=4) did not. The remaining participants (11.1%, n=2) were unsure of the perceived value 


























































Figure 4.6: Perceived Value in the Therapeutic / Medicinal Use of Cannabis and 
Cannabinoids in Cancer Management 
 
4.3.3 Perceived Value in the Therapeutic / Medicinal Use of Cannabis and Cannabinoids 
in Chemotherapy / Radiation Side Effects.  
Participants were asked to indicate whether there was value in the therapeutic / medicinal use of 
cannabis and cannabinoids in the management of the side effects of chemotherapy and radiation. 
Figure 4.7 shows that over half (61.1%, n=11) of the participants found value in the therapeutic / 
medicinal use of cannabis and cannabinoids in chemotherapy / radiation side effects while 16.7% 
(n=3) participants did not. The remaining 22.2% (n=4) of the participants were unsure of the value. 
 
 
Figure 4.7: Perceived Value in the Therapeutic / Medicinal Use of Cannabis and 
Cannabinoids in Chemotherapy/Radiation Side Effects. 
 
Participants who did not perceive value in the therapeutic / medicinal use of cannabis and 
cannabinoids (Figures 4.5, 4.6 and 4.7) were able to state their reason(s). The reasons stated have 

























































Table 4.1: Reasons Stated for No Value Perceived in Cannabis and Cannabinoids 
Reason Stated    
 Frequency Percent Valid Percent 
Due to side effects of Cannabinoids 1 5.6 5.6 
Cannabis & Cannabinoids do not 
work  
2 11.1 11.1 
Lack of research or literature to 
support it 
3 16.7 16.7 
Personal lack of knowledge 1 5.6 5.6 
Other medication is more effective  2 11.1 11.1 
Current legalization status  3 16.7 16.7 
Total 12   
 
4.4 Legalisation  
 
4.4.1 Legality of Cannabis for Therapeutic Purposes 
Participants were asked to indicate their knowledge as to whether cannabis is currently illegal in 
South Africa for therapeutic purposes. The more common response (61.1%, n=11) amongst 
participants was that cannabis is currently not illegal for therapeutic use while some (38.9%, n=7) 
participants stated that cannabis is illegal for therapeutic use. 
 
 






























4.4.2 Legality of Cannabis Within the Confines of One’s Home 
Participants were asked to indicate whether, to their knowledge, cannabis is currently legal in 
South Africa for use in one’s home. Figure 4.9 shows that more than half (61.1%, n=11) of 
participants said that cannabis is currently legal for home use, while some (11.1%, n=2) 
participants stated that cannabis is not legal for home use, and the remaining (27.8%, n=5) 
participants were unsure.  
 
 
Figure 4.9: Legality of Cannabis Within the Confines of One’s Home 
 
4.4.3 Permissibility to Apply to Prescribe Cannabis 
Participants were asked to indicate whether, to their knowledge, they were permitted to apply to 
the Director General of Health to prescribe cannabis for therapeutic purposes. There was an even 
distribution of responses as shown in Figure 4.10, with 33.3% (n=6) of participants stated that they 
could apply to the Director General of Health, 33.3% (n=6) participants stated no, and the 





























































4.5.1 Cannabis and Cannabinoids Are Different Substances 
Participants were asked whether cannabis and cannabinoids are different substances, to which the 
majority of participants 77.8% (n=14) answered yes, while 22.2% (n=4) of the participants 
answered no. There were no participants who were unsure, as illustrated in Figure 4.11. 
 
 
Figure 4.11: Cannabis and Cannabinoids Are Different Substances 
 
4.5.2 Familiarity with the Research and Guidelines Approved for Cannabinoid Prescription 
Participants were asked if they were familiar with the research and international regulations 
regarding approved cannabinoids in managing cancer symptoms and treatment side effects. More 
than half of the participants (55.6%, n=10) were familiar with the guidelines. A further 38,9% 
(n=7) of participants answered no and the remaining 5.6% (n=1) stated that they did not know. 
































Figure 4.12: Familiarity with the Research and Guidelines Approved for Cannabinoid 
Prescription 
 
4.5.3 Sources Used to Obtain Information 
The participants who answered ‘yes’ in Figure 4.12 were asked to state the sources used to obtain 
their information related to cannabinoids, its therapeutics use and side effects. This question 
allowed for multiple responses: the 25 responses received have been tabulated in Table 4.2 below. 
Where participants could stipulate ‘other sources’ a participant (5.6%, n=1) referenced Perez & 
Brady’s Oncology Principles Book. 
 
Table 4.2: Sources used to obtain information 
Information Sources    
 Frequency Percent Valid Percent 
Social Media  3 16.7 16.7 
Conferences 1 5.6 5.6 
Internet & websites 6 33.3 33.3 
Journals 6 33.3 33.3 
Evidence based research and 
clinical trials 
4 22.2 22.2 
From speaking to colleagues 2 11.1 11.1 
A medical professional 
body/association 
2 11.1 11.1 
Other 1 5.6 5.6 






























4.5.4 Dependence Forming Potential of Cannabis 
Participants were asked to indicate which statement best described the dependence-forming 
potential of cannabis. The responses were fairly evenly distributed as depicted in Figure 4.13 and 
outlined below: 
• I do not know whether cannabis is addictive or how addictive it may or may not be: 16,7%, 
n=3 
• Cannabis is a highly addictive substance like opiate drugs and medicines: 27,8%, n=5 
• Cannabis is more addictive than alcohol and tobacco, but not as addictive as opiate drugs 
and medicines: 11,1%, n=2 
• Cannabis is less addictive than alcohol and tobacco: 22,2%, n=4 
• Cannabis causes dependence in less than 10% of people: 22,2%, n=4 
 
 




4.6.1 Symptoms Cannabinoids May Relieve 
Participants were asked which symptoms they thought cannabinoids may relieve. A total of 93 
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Table 4.3: Symptoms Cannabinoids May Relieve  
Symptom    
 Frequency Percent Valid Percent 
Pain 17 94.4 94.4 
Anorexia 15 83.3 83.3 
Nausea 14 77.8 77.8 
Vomiting 10 55.6 55.6 
Depression  6 33.3 33.3 
Insomnia  10 55.6 55.6 
Cachexia  8 44.4 44.4 
General wellbeing  9 50 50 
Weakness 4 22.2 22.2 
Total 93   
 
4.6.2 Stages of Cancer to Consider Cannabinoid Use 
Participants were asked at what stage of cancer they would recommend or consider the therapeutic 
use of cannabinoids in cancer management. The question allowed for multiple responses, and a 
total of 27 responses were received. Figure 4.14 shows that the majority of the participants (72.2%, 
n=13) saw value in the therapeutic use of cannabinoids in palliation, while some participants 
(44.4%, n=8) would consider it for advanced cancers. A single participant (5.6%, n=1) considered 
it for localised and invasive tumours and some (27.8%, n=5) participants would consider it for all 
stages of cancer. While n=5 participants selected “all stages”, thereby implying that they would 
consider it for early (n=0) and localised, non-invasive cancers (n=0), these two options were not 
selected by any of the participants.  
 
 




































4.6.3 Types of Cancer 
For this question participants could choose more than one answer. A total of 87 responses were 
received. Participants were asked what types of cancers they would recommend or consider the 
use of cannabinoids for. As shown in Figure 4.15, almost all the participants (88.9%, n=16) 
participants indicated that they would consider cannabinoids for both carcinomas and sarcomas. 
More than half the participants (61.1%, n=11) indicated leukaemia, and 72.2% (n=13) of the 
participants selected lymphomas.  Many participants (77.8%, n=14) considered cannabinoids for 








4.7.1 Medical Training for Prescribing 
Participants were asked whether practitioners should be required to complete a training course  on 
the human endo-cannabinoid system and prescribing plant-based medicines prior to being 
authorized to prescribe cannabis to patients, to which almost all (94.4%, n=17) participants agreed 





































Figure 4.16: Medical Training for Prescribing 
 
4.7.1.1 HPCSA Practitioners 
Participants could then indicate which practitioner(s) registered with the HPCSA should be 
allowed to prescribe cannabis. This question allowed for more than one response. Table 4.4 depicts 
the 29 responses received from participants.  
 
Table 4. 4: HPCSA Practitioners 
HPCSA Practitioners    
 Frequency Percent Valid Percent 
Oncologists only  7 38.9 38.9 
All Medical Doctors  11 61.1 61.1 
Advanced Nurses only 6 33.3 33.3 
All nurses 2 11.1 11.1 
Dentists 1 5.6 5.6 
Physiotherapists  1 5.6 5.6 
No HPCSA practitioners 1 5.6 5.6 
Total 29   
 
4.7.1.2 AHPCSA Practitioners 
Participants were then asked which allied health practitioner(s) registered with the AHPCSA 
should be allowed to prescribe cannabis. Multiple responses could be chosen in this question. A 



































Table 4.5: AHPCSA Practitioners 
AHPCSA Practitioners    
 Frequency Percent Valid Percent 
Homeopaths 5 27.8 27.8 
Naturopaths 4 22.2 22.2 
Phytotherapists 2 11.1 11.1 
Chiropractors 2 11.1 11.1 
Osteopaths 2 11.1 11.1 
Traditional Chinese Medicine Practitioners 3 16.7 16.7 
Unani Tibb practitioners  2 11.1 11.1 
Ayurveda practitioners  2 11.1 11.1 
None of the above 7 38.9 38.9 
I do not know  6 33.3 33.3 
Total  35   
 
4.7.2 Recommending Cannabis and Cannabinoids as an Adjunct 
Practitioners were asked whether they currently recommend or prescribe cannabis or cannabinoids 
as an adjunct to cancer treatment. Figure 4.17 shows that less than half of the participants (38.9%, 
n=7) participants answered in the affirmative. A larger number of participants (61.1%, n=11) said 
that they did not currently recommend or prescribe cannabis or cannabinoids as an adjunct to 
cancer treatment.  
 
 





























4.7.3 Prescribing Cannabis or Cannabinoids for Symptoms 
In a multiple-choice question, participants were asked which symptoms they would prescribe 
cannabis or cannabinoids for. Table 4.6 illustrates the variation amongst the 81 responses received.  
 
Table 4.6: Symptoms for Which Cannabis or Cannabinoids Would Be Prescribed 
Symptom    
 Frequency Percent Valid Percent 
Pain 18 100 100 
Anorexia  16 88.9 88.9 
Nausea  12 66.7 66.7 
Vomiting 5 27.8 27.8 
Depression 5 27.8 27.8 
Insomnia 9 50 50 
Cachexia 8 44.4 44.4 
General wellbeing 7 38.9 38.9 
Weakness  1 5.6 5.6 
Total  81   
 
4.7.4 Response to Patient’s Independent Use of Cannabis 
Participants were asked to indicate their response to patients independently using cannabis as an 
adjunct to their cancer treatment plan. As shown in Figure 4.18 below, 27.8% (n=5) of participants 
expressed support for their patient’s choice but cautioned them. A further 61.1% (n=11) 
participants responded that their patients could choose for themselves and remained impartial, 
while 11.1% (n=2) advised their patients against using cannabis but continued the treatment plan. 
None of the participants expressed that they fully supported their patient’s choice or refused to 





Figure 4.18: Response to Patient’s Independent Use of Cannabis 
 
4.7.5 Experience in Practice 
 
Participates were asked to rate the number of times patients initiated a discussion regarding using 
cannabis or cannabinoids as an adjunct to their treatment. Some (22.2%, n=4) participants had 
discussions with their patients on a daily basis. A number of participants (38.9%, n=7) discussed 
it several times a week and other participants (38.9%, n=7) discussed with their patients once a 
month, followed by fewer (11.1%, n=2) participants who had discussed with their patients once 
every 2-6 months. A single participant (5.6%, n=1) had never had a patient express interest in 
using cannabis or cannabinoids (Figure 4.19). 
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4.7.6 Approach in Practice 
Participants were asked how often they initiated a conversation with their patients regarding 
cannabis usage. The distribution in Figure 4.20 shows that 5.6% (n=1) of participants stated that 
he / she initiated a conversation with every patient, while 38.9 % (n=7) of participants initiated a 
conversation with some of their patients, and over half (55.6%, n=10) the participants never 
initiated a conversation regarding cannabis use with their patients. 
 
 
Figure 4.20: Approach in Practice 
 
4.7.7 Recommended Cannabis or Cannabinoids 
 
4.7.7.1 Form of Cannabis or Cannabinoids  
Participants were asked which form of cannabis or cannabinoid they would recommend. The 
results shown in Figure 4.21 illustrate a limited number of participants (11.1%, n=2) would 
recommend the cannabis plant while a few participants (22.2%, n=4) would recommend synthetic 
THC (such as Marinol). Most participants (61.1%, n=11) indicated that they would recommend 
CBD. The remaining participants (16.7%, n=3) that had stated ‘other’ stipulated that they would 
not recommend cannabis or cannabinoids altogether. The results are shown in Figure 4.21. 
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4.7.7.2 Administration of Plant-based Cannabis  
Participants were asked to specify which route or method of administration they would recommend 
for the use of plant-based cannabis, and multiple answers could be recorded for this question.  The 
following trends were found from 24 responses and have been tabulated in Table 4.7. The 
participants that stipulated ‘other’ stated that they would prefer internationally registered 
medications or that they did not know which administration form to recommend. 
 
Table 4.7: Preferred / Recommended Administration Forms 
Administration forms    
 Frequency Percent Valid Percent 
Registered cannabis oil extracts  10 55.6 55.6 
Cannabis tea / other edible preparations 3 16.7 16.7 
Smoked  1 5.6 5.6 
Topical applications 3 16.7 16.7 
Cannabis oil extracts that are not 
registered 
1 5.6 5.6 
I would not recommend any plant-based 
cannabis treatments but rather synthetic 
cannabinoids  
3 16.7 16.7 
I would never recommend cannabis-
based medications  
1 5.6 5.6 
Other  2 11.1 11.1 
Total 24   
 
4.7.8 Criteria for Current Prescription 
Participants were asked whether there was a current criterion or guideline they follow to determine 
their prescription of cannabinoids, to which all participants (100%, n=18) participants stated they 






Figure 4. 22: Criteria for Current Prescription 
  
4.7.9 Efficacy of Cannabis in Cancer Management 
Participants were asked to rate their perception of the efficacy of cannabis and / or cannabinoids 
in cancer management. Figure 4.23 shows that cannabis was perceived as effective by 22.2% (n=4) 
of the participants, while just over half of the participants (55.6%, n=10) rated the efficacy as 
neutral. There was one participant (5.6%, n=1) who perceived cannabis as completely ineffective 
and 16.7% (n=3) of participants stated that they did not know whether cannabis was effective or 
not. No participants responded that cannabis was very effective or very ineffective.  
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CHAPTER FIVE: DISCUSSION 
 
5.1 Introduction 
The aim of this study was to determine the knowledge and recommendation of cannabis and 
cannabinoids for cancer management by oncologists in South Africa by means of a questionnaire 
(Appendix C). A total of 60 surveys were distributed electronically, via email, and physically by 
visiting oncology practices, and a total of 18 questionnaires were completed and returned. The 
questionnaires were conducted from May 2019 until June 2020. To the researcher’s knowledge, 
this study represents the first investigation to determine oncologists’ knowledge and 
recommendation of cannabis and cannabinoids for cancer management in South Africa.  
 
The survey yielded a low response rate due to two main factors. The first was related to the global 
pandemic caused by the emergence of corona virus disease (COVID-19, also referred to as 2019 
novel corona virus or 2019-nCoV) caused by severe acute respiratory syndrome corona virus 2 
(SARS CoV-2). This pandemic resulted in severe restrictions and limited access to oncologists 
(Western Cape Government, 2020). The second factor was related to the oncologists themselves – 
there was a general hesitancy to complete the questionnaire, and many oncologists did not have 
the time needed to spend on completing the questionnaire. 
 
Surveys were collected over a 14-month period, with physical trips to oncology practices and 
hospitals in Johannesburg, Pretoria and Durban and follow up emails from the researcher. 
According to the 2018 annual census of clinical and radiation oncologists conducted by the South 
African Society of Clinical and Radiation Oncology, South Africa has 20% fewer oncologists than 
two years ago (Seeth, 2019). An overburdened system may contribute towards a lack of response 
from participants.  
 
One oncologist in particular, who oversees a team of 12 other oncologists in the Pretoria region 
responded to the request to participate in the study by replying by email that: “I've gone through 
this questionnaire without submitting and looked through the information letter provided. To be 
honest the questions in this study are guided to either forcing an oncologist to appear completely 
ignorant on the topic of cannabis or alternatively to endorsing it. I am not going to be part of a 
study that will generate results that will either show oncologists as completely ignorant on the 
topic or as endorsing cannabis use. I doubt any of the other doctors will willingly complete this 
study either.” As such, none of the 12 potential participants from that oncology practice took part 
in the study. However, it is worth mentioning that each question provided varying degrees of 
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agreement or disagreement with follow up questions for the opportunity to explain responses. The 
questionnaire was also approved by both the UJ HDC (Appendix D) and REC committees 
(Appendix E). 
 
The questionnaire consisted of 6 Sections that each explored a different aspect of oncologists and 
their understanding surrounding cannabis and cannabinoids in cancer management. The 
questionnaire was made up of the following Sections: Section A – demographic and work 
experience data; Section B – use and perceived benefits of cannabis and cannabinoids; Section C 
– knowledge regarding the legalization of cannabis; Section D – broad-based questions on 
cannabis and cannabinoids and the sources used to obtain information on them; Section E – 
recommendation and perceived value of cannabis and cannabinoids; and Section F – the 
prescription of cannabis and cannabinoids.  
 
5.2 Demographics 
The demographic information obtained was analysed to determine the typical population of the 
oncologists that took part in the study. Participants were asked their age (4.2.1), gender (4.2.2), 
province they practice in (4.2.3), and years of experience in the field of oncology (4.2.4). The 
results from 18 participants suggest that the average participant was between the ages of 30-39 
years, male, practicing in Gauteng, with 10-19 years of experience in oncology. These results are 
not a true reflection of the demographics of oncologists in SA. Unfortunately, there is a lack of 
sufficient statistics to make comparisons. The HPCSA website does not have a current register of 
medical and radiation oncologists. The majority of the participants were based in Gauteng. As the 
researcher is also based in Gauteng this enabled the researcher to make multiple visits to practices 
in and around Gauteng.  
 
5.3 Perception on the Use of Cannabis and Cannabinoids  
This section of the questionnaire was aimed at understanding whether participants supported and 
saw value in the medicinal use of cannabis and cannabinoids in cancer management. When 
referring to section 4.3, participants had an almost even distribution between whether or not they 
supported the use of cannabis and cannabinoids, where 55.6% (n=10) supported the therapeutic / 
medicinal use of cannabis and cannabinoids and  44.4% (n=8) of participants did not support the 
therapeutic / medicinal use of cannabis and cannabinoids. 
 
This may be due to the fact that no commercial plant-derived cannabis products are currently 
registered by the South African Health Products Regulatory Authority (SAHPRA) for medical use. 
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Medical practitioners in South Africa can legally prescribe medicinal cannabis products with 
approval from the Department of Health (DOH) and the South African Health Products Regulatory 
Authority (SAHPRA) via the Section 21 application route (SAHPRA, 2020). 
 
In expressing the perceived value of cannabis and cannabinoids in cancer management, 66.7% 
(n=12) of the participants found value in the therapeutic / medicinal use of cannabis and 
cannabinoids in cancer management, while 22.2% (n=4) of respondents did not. The remaining 
11.1% (n=2) were unsure of the perceived value.  
 
The following trends were found: All participants in section 4.3.1 who supported the therapeutic 
or medicinal use of cannabis and cannabinoids, also saw value in its use in cancer management. 
Of the participants (44.4%, n=8) who stated that they do not support the use of cannabis and 
cannabinoids, 22.2% (n=4) did not see value in its use in cancer management, while 11.1 % (n=2) 
were unsure and the remaining 11.1% (n=2) did see value in the therapeutic use of cannabis in 
cancer management. 
 
In addition, 61.1% (n=11), of the participants found value in the therapeutic / medicinal use of 
cannabis and cannabinoids in chemotherapy / radiation side effects while 16.7% (n=3) of 
participants did not. The remaining 22.2% (n=4) of the participant group were unsure of the value. 
 
Participants who answered ‘No’ to the questions in sections 4.3.1-4.3.3 were asked to indicate 
their reasoning. Multiple responses could be recorded, and 12 responses were received from the 8 
participants who qualified for this question. In descending order, the following responses were 
received: current legalisation status and lack of research or literature to support it (16.7%, n=3), 
cannabis and cannabinoids do not work or other medication is more effective (11.1%, n=2), side-
effects of cannabinoids, and personal lack of knowledge (5.6%, n=1). 
 
A 2016 publication by Abrams reasons that a concern to the oncologist is the lack of data/research 
on which to base treatment recommendations.  Given the nature of the drugs that they prescribe, 
oncologists are used to seeing strong evidence of a favourable risk–benefit ratio before 
recommending a therapeutic intervention (Abrams, 2016). As mentioned by Abrams (2016) 
“Regrettably, most oncologists were trained during the era of cannabis prohibition and have no 




A 2019 systematic review by Gardiner et al. to determine ‘Health professional beliefs, knowledge, 
and concerns surrounding medicinal cannabis’ reviewed 26 studies globally. The survey included 
medical practitioners, pharmacists, nurses, and allied health professionals and aimed to establish: 
i) how health professionals feel about the use of medicinal cannabis in clinical practice; ii) how 
knowledgeable health professionals are regarding medicinal cannabis; and iii) what concerns exist 
for health professionals regarding the delivery of medicinal cannabis. The review investigated 18 
studies in which medical practitioners found no data to reject the clinical usefulness of medical 
cannabis. From the 26 studies, six reported support for the clinical usefulness of medicinal 
cannabis by the majority of participants while an additional 5 studies presented data to support the 
use of medical cannabis as a viable treatment option. However, a single study reported a lack of 
confidence in using medical cannabis as a treatment option while 3 studies revealed participants’ 




Section C explored oncologists’ knowledge of the current legalisation status of cannabis and 
cannabinoids in South Africa. The most common response (61.1%, n=11) amongst participants 
was that cannabis is currently not illegal for therapeutic use while some (38.9%, n=7) participants 
stated that cannabis is illegal for therapeutic use (4.4.1).   
 
Participants were asked whether they could apply to the Director General of Health to prescribe 
cannabis for therapeutic purposes (4.4.3). An even distribution was obtained where 33.3% (n=6) 
of participants answered yes, no and I do not know, respectively. Section 21 of the Medicines Act 
read together with General Regulation 29 published in terms of the Medicines Act, allows for an 
authorised practitioner to apply to the Director General of the National Department of Health for 
individual patient access to unregistered medicines. This includes medicines containing cannabis, 
THC or CBD (SAHPRA, 2020).  
 
The current legal status of cannabis as per the ‘Cannabis for Private Purposes Bill’ was introduced 
to: i) respect the right to privacy of an adult person to possess cannabis plant cultivation material; 
ii) to cultivate a prescribed quantity of cannabis plants; and iii) to possess a prescribed quantity of 
cannabis; and to consume cannabis (Cannabis Bill, 2020). As a South African citizen, it is therefore 
legal to possess cannabis within one’s personal space as outlined above. Specifically, the use of 
cannabidiol (CBD) is legal and freely available in South Africa (Hassan, 2020). The Department 
of Health announced in May 2019 that CBD products can be legally purchased as long as it does 
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not exceed the maximum daily dose of 20 milligrams and sellers do not claim to treat or cure any 
specific condition (De Wet, 2019)  
 
When asked whether cannabis is legal for use in one’s own home, 61.1% (n=11) of participants 
answered correctly, while 11.1% (n=2) stated cannabis was illegal for home use and a further 
27.8% (n=5) were unsure of its legal status. As mentioned above, cannabis was made legal for 
personal use by the Constitutional Court in September 2018 (Cannabis Bill, 2020). 
 
5.5 Knowledge 
Section D evaluated the level of knowledge surrounding cannabis and cannabinoids. As reported 
in section 4.5.1, 77.8% (n=14) of participants stated that cannabis and cannabinoids are different 
substances while the remainder (22.2%, n=4) were under the impression that cannabis and 
cannabinoids were the same substance. Cannabinoids, such as CBD and THC, are found in the 
cannabis plant. They are components of the cannabis plant, but not the whole plant. Therefore, 
cannabis and cannabinoids are different substances (SAHPRA, 2020).  
 
Uruguay was the first country in the world to completely legalise the cannabis market for medical, 
scientific, industrial, and recreational use (Maybin, 2019). The U.S. Food and Drug Administration 
approved Marinol (a synthetic formulation of THC, otherwise known as dronabinol) for medical 
uses in 1985. Since then, the drug has been legal in all 50 states, however, because it is a regulated 
pharmaceutical drug, you need a prescription to purchase and use Marinol (Pantekoek, 2020). 
Despite the growing number of countries that have legalized the medicinal use of cannabis, an 
international guideline does not exist. The medical use of cannabis, cannabinoids or cannabis-
based pharmaceuticals is legal in 57 countries across the globe. This includes Argentina, Australia, 
Brazil, Canada, Chile, Colombia, Croatia, Czech Republic, Denmark, Ecuador, Finland, Germany, 
Greece, Ireland, Israel, Italy, Jamaica, Lebanon, Lithuania, Luxembourg, Malawi, Malta, the 
Netherlands, New Zealand, North Macedonia, Norway, Peru, Poland, Portugal, Sri Lanka, 
Switzerland, Thailand, the United Kingdom, Uruguay, Zambia, and Zimbabwe. Countries that 
have legalised the recreational use of cannabis are Australia, Canada, Georgia, South Africa, and 
Uruguay, as well as 35 states within the United States of America. The recreational use of cannabis 
therefore allows citizens the ability to choose to use cannabis for medicinal purposes (Legality of 
cannabis, 2020). 
 
Research in the field of cannabis and oncology is ever growing. In this research study, 55.6% of 
participants (n=10) indicated that they were familiar with the international guidelines regarding 
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approved cannabinoids in managing cancer symptoms and treatment side effects and research, 
while 38,9% (n=7) of participants answered no and the remaining 5.6% (n=1) stated that they did 
not know about international guidelines or research. An article in the South African Medical 
Journal by Van Rensburg et al. (2020) concluded that “few healthcare practitioners have been 
adequately equipped with knowledge of the evidence, indications and legislation to support the 
safe use of medical cannabis.” In a similar comparison, previously discussed in section 5.4 of this 
discussion, Gardiner et al. (2019) reported that there was universal self-reported lack of knowledge 
regarding legislative and clinical domains. 
 
In this study, only the participants’ self-perception regarding their knowledge was assessed. This 
is consistent with the findings of the systematic review conducted by Gardiner et al. (2019). These 
authors found that all the studies included in their systematic review measured self-perceived 
knowledge, which meant that the assessment of knowledge is not an accurate reflection of the true 
extent of the participants’ knowledge, but rather a reflection of their own perception of their 
knowledge. Participants in general rated their knowledge as poor across legislative and clinical 
fields and highlighted the need for further education and training and access to information.  
 
Participants who indicated that they were familiar with international guidelines and research could 
then stipulate the sources used to obtain the information, in which internet & websites (33.3%, 
n=6), journals (33.3%, n=6), and evidence-based research and clinical trials (22.2%, n=4) ranked 
highest in their responses. A plethora of information regarding cannabis exists online, a Google 
search of ‘Cannabis Journals’ yields 7 960 000 results. Practitioners may rely on evidence-based 
resources for information, followed by online learning, news and media, and their patients’ past 
experiences to improve their knowledge (Gardiner et al., 2019).  
 
Cannabis is often viewed as a vice rather than a virtue (O'Grady, 2020). When asked about the 
dependence forming potential of cannabis, participants had varying responses as shown in section 
4.5.4 and outlined below: 
• Cannabis is a highly addictive substance like opiate drugs and medicines: 27,8%, n=5 
• Cannabis is less addictive than alcohol and tobacco: 22,2%, n=4 
• Cannabis causes dependence in less than 10% of people: 22,2%, n=4 
• I do not know whether cannabis is addictive or how addictive it may or may not be: 16,7%, 
n=3 
• Cannabis is more addictive than alcohol and tobacco, but not as addictive as opiate drugs 




Before prescribing any medicine, the harm-benefit ratio should be evaluated (Van Rensburg et al., 
2020). Cannabinoids have a favourable safety profile when compared with other analgesic 
medications. There is concern regarding the addictive potential of cannabis. The risk of 
dependence on cannabis is reported to be 9% in long-term users, significantly less than the 
addiction rates of heroin, cocaine, alcohol, and prescribed anxiolytics (Wilkie et al., 2016). 
 
Similarly, a 2007 study aimed to assess the harm of drugs of potential misuse, in which heroin, 
cocaine, barbiturates, street methadone and alcohol were the ranked the five most harmful 
substances, tobacco is featured in 9th position while cannabis featured in the 11th position. The 
scores were analysed according to the physical harm, dependence and social harm resulting from 
use of each substance (Nutt et al., 2007). In this study, 27,8% (n=5) of the participants rated 
cannabis as being highly addictive and on par with opiate drugs and medicines; 11,1% (n=2) rated 
it more addictive than alcohol and tobacco but less addictive than opiate drugs and medicines; and 
22,2% (n=4) rated it less addictive than alcohol and tobacco.  Three participants (16,7%, n=3) did 
not know if it is addictive or how addictive it might be, and four participants (22,2%, n=4) 
indicated that is causes dependence in less than 10% of people.  
 
Although it was not explored in this study, other concerns for practitioners (apart from 
dependence) that became apparent in other studies is the risk of adverse reactions and drug-drug 
reactions. Gardiner et al. (2019) found that when it comes to the use of medicinal cannabis and 
cannabinoids, health professionals are concerned about harm to the patient in the form of 
psychiatric adverse drug reactions, and the risk of drug-drug interactions – especially since patients 
who are in need of medical cannabis and cannabinoids generally suffer from multiple or significant 
co-morbidities and are often on many conventional medications. Van Rensburg et al. (2020) stated 
that the use of cannabis for medicinal purposes may be associated with a higher risk of unwanted 
or adverse reactions and effects than active and placebo controls, and that they may be involved 
in clinically significant drug-drug interactions. 
 
5.6 Recommendation and Perceived Value 
While the research of the medicinal use of cannabis and cannabinoids may still be lacking in many  
areas, current research supports their use (with varying degrees of efficacy) for the following 
conditions: chronic pain, cancer, chemotherapy-induced nausea and vomiting, anorexia and weight 
loss associated with HIV, irritable bowel syndrome, epilepsy, spasticity, Tourette syndrome, 
amyotrophic lateral sclerosis, Huntington’s disease, Parkinson’s disease, dystonia, dementia, 
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glaucoma, traumatic brain injury, addiction, anxiety, depression, sleep disorders, posttraumatic 
stress disorder, and schizophrenia and other psychoses. The efficacy of cannabis in the 
aforementioned symptoms and conditions may also link to the overall perceived efficacy of 
cannabis in cancer treatment, as discussed at the end of this chapter (Dariš et al., 2019; Freeman 
et al, 2019; Klumpers and Thacker, 2019)  
 
Section 4.6.7 yielded 93 responses from participants, with pain (94.4%, n=17), anorexia (83.3%, 
n=15), nausea (77.8%, n=14), vomiting (55.6%, n=10) and insomnia (55.6%, n=10) being the most 
common responses. This may be owing to the recent advancement of research in these specific 
symptoms or alternatively, that they are the most prominent symptoms associated with cancer and 
cancer treatment (CRUK, 2018a; WHO, 2018). 
 
Patients are often more concerned about the side effects that are a result of chemotherapy than the 
chemotherapy treatment itself (Stewart, 2020). A study by Passik et al. (2001) found that hair loss, 
vomiting, infection, nausea, and weight loss were ranked as the most feared side effects of cancer 
treatment for the study group as they began treatment. They concluded that effective treatments 
could relieve the fears of patients on treatment and that patients' fears about treatment are fluid and 
malleable. Patients' fears of suffering related to chemotherapy treatment change in response to the 
provision of adequate management. 
 
The use of cannabis and cannabinoids may alleviate some of the side-effects of chemotherapy 
treatment. One participant (5,56%, n=1) of the study noted that “patients are desperate to try 
anything to help their symptoms”. The American Cancer Society has stated that there is evidence 
that cannabis helps with the side-effects of chemotherapy and even the treatment of cancer itself 
(ACS, 2020a). A Canadian study found that chronic pain patients treated with cannabis reported 
reduced pain and improved quality of life when compared with a control group taking traditional 
painkillers. The cannabis group also reported decreased anxiety, depression, and fatigue, 
indicating that cannabis not only relieved physical pain, but also alleviated the psychological and 
emotional impact of the pain (Ware et al., 2015). 
 
Where cancer staging in concerned, cannabis may prove useful when the patient is in palliative 
care. Cannabis could also be used in all stages owing to its antitumour effects. The inhibition of 
cell growth, viability, proliferation and invasion, enhanced apoptosis, and suppression of specific 
proinflammatory cytokines are generally similar to the antitumour effects of plant-derived 
cannabinoids. (Dariš et al., 2019). This is consistent with the findings in section 4.6.2, in which 
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the majority of participants recommended the use of cannabis and cannabinoids in palliative care 
(72.2%, n=13), followed by 44.4% (n=8) that would consider it for advanced cancers. A participant 
(5.6%, n=1) considered it for localised and invasive tumours and some (27.8%, n=5) participants 
would consider it for all stages of cancer. While 27.8% (n=5) of participants selected “all stages”, 
thereby implying that they would consider it for early (n=0) and localised, non-invasive cancers 
(n=0), these two options were not selected by any of the participants. 
 
Gardiner et al. (2019) commented that regardless of pre-conceived beliefs, the relative support for 
medicinal cannabis increased if all other treatment options were exhausted or if therapy was to be 
used in the palliative domain. A mini review by Cyr et al. (2018) on cannabis in palliative care 
discusses a series of nine challenges and practical recommendations for practitioners. The clinical 
usefulness of cannabinoid-based medicines, still considered by many to be limited to pain control, 
appears to encompass a much broader range of symptoms encountered in palliative care settings. 
Considering these findings, now may be time to re-examine whether these compounds should be 
offered earlier in the course of a comprehensive palliative care strategy, particularly for patients 
who have had prior positive experience regarding the alleviation of symptoms other than pain. The 
review highlights that cannabis could play an important role in palliative care from a pain 
perspective as well as the alleviation of other symptoms experienced by cancer patients. 
 
Cancer side effects can be brutal – nausea, pain, anxiety, vomiting, insomnia, and lack of appetite, 
to name just a few (ASCO, 2017). Many patients with cancer diagnoses are convinced, based on 
anecdotal evidence, that cannabis, particularly THC and/or cannabidiol (CBD), may cure their 
cancers (Abrams and Guzmán, 2020). A broad-spectrum substance such as cannabis, which caters 
to the disease symptoms and treatment side-effects, may prove useful as therapeutic adjunct. 
Numerous studies have shown the inhibitory, anti-metastatic and cytotoxic effects of cannabis and 
cannabinoids on different cancer cell types in vitro and in animal studies. Dariš et al. (2019) found 
that cannabinoids were able to effectively modulate tumour growth in different in vitro and in 
vivo cancer models, however, these anticancer effects appear to be dependent on cancer type and 
drug dose. Similarly, it was reported that cannabinoids induce tumour cell death and inhibit tumour 
angiogenesis and invasion in animal models of cancer, and there are indications that they act 
similarly in patients with glioblastoma (Velasco et al., 2016b).  
 
The endocannabinoid system may play a dual role on the regulation of tumour generation and 
progression. Administration of THC and other cannabinoids exert anticancer actions in animal 
models of cancer. THC and other cannabinoid receptor-ligands induce cancer cell death and inhibit 
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tumour angiogenesis. Cannabinoids enhance the anticancer activity of other antineoplastic agents 
in animal models of cancer (Velasco et al., 2016a). 
 
Bogdanović et al. (2017) conducted a literature survey of medical and scientific databases with a 
focus on the biological and medical potential of cannabinoids in cancer treatment. The results of 
their review show that cannabinoids have specific cytotoxicity against tumour cells, while 
protecting healthy tissue from apoptosis. A few studies have investigated the possible synergistic 
effects of cannabinoids with standard oncology therapies, concluding that further studies require 
extensive monitoring of the effects of cannabinoids alone or in combination with standard 
anticancer strategies. With such knowledge, cannabinoids could become a therapy of choice in 
contemporary oncology. 
 
This study revealed that participants would consider the use of cannabinoids in the following types 
of cancer: 
• Carcinomas (88.9%, n=16) 
• Sarcomas (88.9%, n=16) 
• Leukaemia (61.1%, n=11) 
• Lymphomas (72.2%, n=13) 
• Myelomas (77.8%, n=14) 
• Brain & spinal cord cancers (94.4%, n=17) 
 
The above results indicate that the participants saw value in the use of cannabinoids in a number 
of cancer types rather than confined to one specific type. It is worthwhile to mention that all the 
participants that selected “All Stages” in section 4.6.2, also selected all types of cancers in section 
4.6.3. Similarly, the participants that selected palliation, or advanced stage of cancer, 
correspondingly selected carcinomas, sarcomas, myelomas and brain and spinal cord cancers. 
 
While leukaemia was selected by fewer participants than the other options, a 2017 in vitro study 
revealed that CBD and THC, when used individually without chemotherapy treatment, killed 
leukaemia cells. However, using cannabinoids after chemotherapy resulted in greater induction of 
apoptosis. (Scott et al., 2017). Studies on a wide range of cell lines, including glioma, breast, 
prostate, endothelial, liver, and lung cell lines have revealed that THC is efficacious in various 
cancers in different degrees. However, there have also been reports of THC increasing cell 
proliferation. The study by Cridge and Rosengren (2013) compared various cell lines and the effect 
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THC, CBD and synthetic cannabinoids had on cell proliferation. The data captured revealed that 
6 out of the 22 cell lines tested reflected an increase in proliferation. CBD and synthetic 
cannabinoids decreased proliferation in the cell lines tested. Thus, the study concludes that the role 
of compounds such as Δ9-THC is not well understood, and its effects are possibly regulated by a 
range of factors that are yet to be determined. A possible factor is the increased expression of CB1 
and CB2 receptors in specific cell lines. There is evidence which suggests the degree of increased 
expression correlates with tumour aggression and progression (Cridge and Rosengren, 2013). CBD 
is well known for its anti-tumour properties in breast, lung, colon, and prostate cancers 
(Shrivastava et al., 2011). When considering the use of cannabis as a whole plant, or synthetic 
cannabinoid-pharmaceuticals that contain both THC and CBD in varying ratios, a study done on 
mice revealed that a 1:1 combination of THC: CBD in fact triggered the death of melanoma cells 
(Glodde et al., 2015). 
 
Aside from the management of symptoms, an increasing number of in vitro and animal-model 
studies supports a possible direct anticancer effect of cannabinoids by way of a number of different 
mechanisms involving apoptosis, angiogenesis, and inhibition of metastasis. Despite a perceived 
absence of clinical trials, there are a substantial number of clinical trials that have been done on 
cannabinoids in cancer and other conditions, and abundant anecdotal reports exist that describe 
patients having remarkable responses to oral high-potency cannabis as an anticancer agent 
(Abrams, 2016).  
 
A search for clinical trials on the use of cannabinoids in cancer yields numerous results, such as: 
i) a study showing benefits of cannabinoids in glioblastoma (MGC Pharmaceuticals, 2020), ii) a 
review concluding benefit in the use of medical cannabinoids in chronic and neuropathic pain in 
advanced cancer (Blake et al., 2017),  and iii) a positive response with reduced solid tumour size 
using pharmaceutical grade synthetic cannabidiol (Kenyon et al., 2018), to name a few.  
 
A report developed by the University of Sydney acknowledges that the clinical evidence regarding 
medicinal cannabis has received less attention than it merits. Scientists, clinicians, and patients 
seeking access to this evidence have found it difficult to separate evidence-based research from 
the wealth of anecdotal and less rigorously obtained experimental results. The report concluded 
that the amount of clinical evidence currently available regarding medicinal cannabis is small. The 
field of medicinal cannabis has been constrained and, in many countries, prohibited or actively 
discouraged through stringent regulatory, legal, and social barriers. Nonetheless, there is strong 
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evidence demonstrating the effectiveness of medicinal cannabis in treating the symptoms of pain, 
nausea, vomiting and appetite in cancer patients (MGC Pharmaceuticals, 2020). 
 
Future research will help clarify the actions of the cannabinoids which will be critical in the 
ongoing development of these compounds (Cridge and Rosengren, 2013). 
 
5.7 Prescription 
In order to ascertain a benchmark for cannabis prescription, it is useful to know the scope of 
practice for practitioners prescribing it, the interest expressed, the need for education and training, 
and the criteria for administering it. This section aims to explore the prescription trends in 
oncologists’ practices.  
 
Section 4.7.1 explored the need for education or training on the human endo-cannabinoid system 
and the prescription of plant-based medicines before being able to prescribe cannabis and 
cannabinoids to patients. This section further explored the prescription of cannabis and 
cannabinoids by determining which practitioners from the HPCSA or the AHPCSA the 
participants thought should be allowed to prescribe these substances – for these two questions 
participants were able to select multiple responses.   
 
As seen from Figure 4.16, n=1 (5.6%) participant selected that practitioners should not undergo 
training prior to prescribing cannabis. In the next two questions, the same participant also selected 
that none of the practitioners registered with the either the HPCSA or the AHPCSA should be 
allowed to prescribe cannabis to patients. The participant did however recommend cannabis as an 
adjunct to cancer treatment (section 4.7.2). All the other participants (94.4%, n=17) selected that 
practitioners should complete training before being able to prescribe cannabis (Figure 4.16).  
 
A 2020 study evaluated current regulatory regimes of medical cannabis using peer-reviewed and 
grey literature as well as personal communications across several countries. Despite differences in 
their regulatory approaches to medical cannabis, all countries agree on the need for continued 
education for physicians and other health care professionals. The researchers concluded that 
physicians’ further education and the continuing development of guidelines for prescribing is 
crucial. Training on medical cannabis is required for medical students in higher education so that 




Similarly, a survey of 425 Canadian physicians found that the physicians were most keen to learn 
about the potential risks, safety, warning signs and precautions around the use of medicinal 
cannabis, and that they perceived their largest knowledge gap to be about dosing and treatment 
plans.  Seventy-one percent of respondents reported that they would feel more comfortable 
discussing cannabis for therapeutic purposes with patients/patient family members if they had 
more education about it, and 70% felt that with more education they would be better able to treat 
patients using cannabis (Ziemianski et al., 2015). 
 
South African medical professionals, ranging from GPs to dietitians and psychologists, who 
complete Cheeba Cannabis Academy’s 7-module Medical Cannabis CPD online course will now 
be eligible for 8 HPCSA-approved CPD points. The course is not restricted to only HPCSA 
registered professionals – any member of the general public who elects to attend the course may 
do so. However, CPD points are only awarded to medical professionals registered with the 
HPCSA. This is the first CPD-approved course on cannabis education in Africa (Medical 
Academic, 2020).  
 
With regards to HPCSA practitioners, most of the participants selected that either oncologists 
(38.9%, n=7), all medical doctors (61.1%, n=11), or advanced nurses (33.3%, n=6) should be able 
to prescribe it. In the study by Ziemianski et al. (2015), when asked which health care professionals 
should be authorized to approve cannabis for therapeutic purposes, 85% reported that specialist 
physicians, and 74% reported that family physicians, should have this authority. 
 
Where various AHPCSA practitioners were proposed as cannabis prescribers, the majority of the 
participants (38.9%, n=7) selected “none of the above”, while 5 (27.8%) participants selected that 
homeopaths should be able to prescribe it, followed by naturopaths (22.2%, n=4) and traditional 
Chinese medicine practitioners (16.7%, n=3). While cannabis and cannabinoids are available as 
whole plant cannabis, as well as natural or synthetic cannabinoids, only n=2 (11.15%) of the 
participants selected phytotherapists (herbal medicine practitioners). Many doctors and medical 
professionals reject alternative therapies due to a lack of confidence in their efficacy, differences 
in training and education, misconceptions, and a lack of understanding of each discipline (Nelson 
et al., 2019) However, The use of cannabis is an integral part of the traditional armamentarium of 
various CM modalities and various preparations may be used for medicinal purposes as treatment 





Within the field of Homeopathy, cannabis has been used in potentized, diluted form and tincture 
form since 1830. Samuel Hahnemann, the founder of Homeopathy, wrote about the use of both 
Cannabis sativa and Cannabis indica in his book, Materia Medica Pura, originally published in 
1846 (Hahnemann, 2002). William Boericke, an American homeopath wrote in the ninth edition 
of his book The New Manual of Homeopathic Materia Medica, published in 1927 that both 
Cannabis indica and Cannabis sativa should be dosed as a tincture (Boericke, 2007). 
 
Of the total participants in this study, 38.9% (n=7) currently recommend or prescribe cannabis as 
an adjunct to cancer treatment (section 4.7.2), while the remainder (61.1%, n=11) do not.  A recent 
survey of 237 medical oncologists in the United States was conducted to determine the beliefs, 
practices, and knowledge regarding marijuana used therapeutically. In the study, nearly half of 
oncologists (45.9%) had recommended medicinal use of marijuana, despite the study’s finding 
that a significant proportion do not feel sufficiently knowledgeable to make recommendations 
(Braun et al., 2018). 
 
The next question (section 4.7.3) explored which symptoms of cancer or cancer treatment the 
participants would recommend cannabis or cannabinoids for. This was an open question where 
participants could select multiple options, and a total of 81 responses were received. In order of 
decreasing frequency, the symptoms selected were: pain (100%, n=18), anorexia (88.9%, n=16),  
nausea (66.7%, n=12), insomnia (50%, n=9), cachexia (44.4%,n=8), general wellbeing (38.9, 
n=7), vomiting (27.8%, n=5), depression (27.8%, n=5), weakness (5.6%, n=1). 
 
The data from this study demonstrates a consistent trend regarding cannabis usage as an adjunct 
treatment of pain.  There is significant evidence for the effectiveness of cannabis and cannabinoids 
in treating cancer-related pain. A 2020 systematic review of 96 studies assessed the evidence of 
the efficacy and safety of cannabis and cannabinoids as adjuvant therapies in palliative and 
supportive oncology care. From the 2,267 articles and included 96 studies screened, the most 
frequent outcomes assessed were the efficacy of cannabis and cannabinoids for: pain (41.7%, 
n=40; with 17 indicating improvement), nausea and vomiting (27.1%, n=26; with 20 indicating 
improvement), and cachexia (22.9%, n=22; with 2 indicating improvement) (Jugl et al., 2020). 
 
Similarly, Abrams (2016) concluded that cannabis and cannabinoids are useful in managing 
symptoms related to cancer and its treatment. Exciting preclinical evidence suggests that 
cannabinoids are not only effective in the treatment of cancer, but also in the prevention of 
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chemotherapy-induced peripheral neuropathy. Cannabinoids could be used synergistically with 
opioids in the relief of pain. 
 
The majority of the participants in this study were either supportive of their patient’s independent 
choice to use cannabis as an adjunct to their cancer treatment plan, but cautioned them (27.8%, 
n=5) or remained neutral, allowing patients to decide for themselves (61.1%, n=11). The remaining 
participants (11.1%, n=2) advised their patients against it, but continued their treatment plan. None 
of the participants (n=0) fully supported their patient’s choice or refused to treat them based in 
their choice.  
 
Ziemianski et al. (2015) conducted a study on cannabis in medicine, specifically the knowledge, 
experience, attitudes, and barriers of physicians in Canada. The study reported that most of the 
participants (79%) reported having been approached by a patient and/or his/her family to discuss 
the use of cannabis for therapeutic purposes, while 39% reported initiating a discussion with a 
patient and/or his/her family on the use of cannabis for therapeutic purposes. A similar study in 
the United States reported that seventy-eight percent of the 186 oncologists who endorsed 
discussing medical marijuana with their patients reported that these conversations were more often 
initiated by the patients and their families than by the oncologist (Braun et al., 2018). 
 
Patients may elect to disclose or discuss cannabis usage with their oncologist while undergoing 
treatment. The study revealed that oncologists may have daily (22.2%, n=4), weekly (38.9%, n=7) 
or monthly (38.7%, n=7) discussions with patients regarding cannabis usage that were initiated by 
the patients themselves (section 4.7.5).. A 2016 review of findings from the 2012 National Health 
Interview Survey found that patients did not disclose the use of complementary and alternative 
medicine (CAM) due to a number of reasons, including past or potential discouragement or 
negativity from their physician, lack of knowledge regarding CAM, lack of time or initiation to 
discuss CAM from their physician, not using CAM at the time, or belief that their medical 
practitioner did not need to know about adjunct therapies (Jou and Johnson, 2016).  
 
Participants were also asked to describe their approach in practice regarding initiating 
conversations surrounding cannabis usage. Section 4.7.6 shows that 5.6% (n=1) of participants 
stated that he initiated a conversation with every patient. This participant further commented that 
he  was currently conducting a clinical trial with a group of his patients and that this conversation 
was therefore essential as the use of cannabis may have  adverse effects on the specific 
chemotherapy regimen prescribed for the clinical trial, or affect the outcome of the trial. While 
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38.9 % (n=7) of participants initiated a conversation with some of their patients, over half (55.6%, 
n=10) the participants never initiated a conversation regarding cannabis use with their patients. 
 
A study consisting of 82 advanced cancer patients assessed how providers responded to patients 
mentioning complementary and integrative medicine (CIM) during routine oncology visits. CIM 
was mentioned in 34% of the total observed visits. Patients initiated conversations about CIM 
(76%) more than healthcare providers (24%) did. Patients mentioning CIM may indicate a 
preference for, or interest in, non-pharmacological adjunctive treatment options, however, 
practitioners’ responses inhibited further talk in 44% of observations and promoted discussion in 
56% of observations (Koenig et al., 2015). 
 
When asked which forms of cannabis or cannabinoid they would recommend (section 4.7.7.1), the 
majority of the participants in this study favoured CBD (61.1%, n=11) over synthetic THC such 
as Marinol (22.2%, n=4) or the whole cannabis plant (11.1, n=2), while the remaining participants 
(16.7%, n=3) would not recommend cannabis or cannabinoids at all. Although participants had 
favoured CBD in their recommendation, when considering cannabis as a whole plant (a lesser 
favoured option in the data collected), combining THC with CBD can help reduce THC-mediated 
side-effects (Thomas, 2020).  
 
In the South African context, CBD is more easily accessible than THC. Since the 2018 
decriminalization of cannabis came into effect in South Africa, CBD has become increasingly 
popular (Ndongeni-Ntlebi, 2020). This is also noted in section 4.7.7.2, where participants could 
indicate the route or method of administration they would recommend for plant-based cannabis. 
The majority of the participants (55.6%, n=10) selected registered oil extracts. This could be due 
to the standardization of active ingredients in the medicine or the clinical testing involved with 
registered products. To date, there are no registered cannabis containing medicines in South Africa 
and any access to these medicines is via the section 21 application process (SAHPRA, 2020).  
 
Cannabis products that are commercially sold in South Africa have not been regulated or registered 
by SAHPRA. Sativex is an oromucosal spray of a formulated cannabis extract that contains the 
principal cannabinoids THC and CBD, as well as specific minor cannabinoids and other non-
cannabinoid components. Regulatory approval of Sativex has been obtained in numerous countries 
outside the United States for the treatment of spasticity due to Multiple Sclerosis (GWPharm, 
2020). Marinol capsules, containing dronabinol (synthetic THC), are registered in the USA and 
the UK, and are indicated for use in chemotherapy-induced nausea and vomiting, and to treat 
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anorexia associated with weight loss in patients with AIDS. Marinol was previously registered in 
South Africa, but is no longer marketed in this country (SAHPRA, 2020). 
 
When asked, all participants responded that there was no current criterion or guideline they follow 
to determine their prescription of cannabinoids. Based on the scheduling of cannabis products in 
South Africa and lack of tested and registered cannabis products available in South Africa, there 
is no standardization or criteria for dosages for South African oncologists to refer to (SAHPRA, 
2020). Globally, due to limited evidence on dosage and interval, there are no validated dosage 
recommendations. However, physicians may use clinical trials and journals as a guide for 
prescribing cannabis in clinical practice.  
 
Some studies add valuable insight into cannabis dosing. A systematic review of CBD dosing in 
clinical populations identified the wide active dosing range of CBD (<1 to 50 mg/kg/day) within 
a variety of medical conditions. The review further indicated that studies that used higher doses 
tended to have better therapeutic outcomes compared to lower doses overall (Millar et al., 2019). 
 
In 2016, The Minnesota Department of Health (MDH) conducted a review of medical cannabis 
studies relating to chemical compositions and dosages for medical conditions. The study described 
the recommended dosage for specific conditions based on evidence from clinical trials. Trials on 
cancer associated pain suggested that Sativex offered better pain control than placebo. In addition, 
the maximum daily dosage stipulated was 10 sprays of Sativex per day, providing 27 mg THC and 
25 mg CBD per day (Minnesota Department of Health, 2016). 
 
The same review by the MDH assessed clinical trials of dronabinol, synthetic THC, in which daily 
doses of 30 to 80 mg/day in divided doses was administered. However, not everyone can tolerate 
these doses, thus the FDA recommends a lower dronabinol dose for chemotherapy-induced nausea 
and vomiting, stating most patients respond to 5 mg three or four times daily (Minnesota 
Department of Health, 2016).  
 
As mentioned previously, Van Rensburg et al. (2020) concluded that “few healthcare practitioners 
have been adequately equipped with knowledge of the evidence, indications and legislation to 
support the safe use of medical cannabis”.  
 
This, however, empowers patients to titrate their dose according to the intensity of their symptoms. 
The following outlines some suggestions for the dosage and titration of cannabis therapeutically. 
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Where dosing of CBD is concerned, it is suggested that patients may begin with a low starting 
dose of 2 mg CBD and increase doses gradually each day until a threshold dose is determined. 
There are no published daily maximum dosages and minimal risks of fatal overdose with CBD. It 
is further advised that exceeding 20 mg to 30 mg of THC per day may increase adverse events 
without improving efficacy (MacCallum and Russo, 2018; CPhA, 2020). The recommended 
starting dosage for Marinol in patients undergoing chemotherapy is 5 mg/m2, for a total of 4 to 6 
doses per day (Abbvie Inc, 2017) 
 
A patient’s response to cannabis may vary by their concurrent use of other medications, co-
morbidities, prior use of cannabis, tolerance level, age, gender, genetics, biochemistry, diet and 
foods, route of administration (inhalation, ingestion, product formulation), and the THC and / or 
CBD concentrations of the product they are taking (Royal CBD, 2020; University of California, 
2020). The standardization of cannabis products is exceedingly difficult as products vary in terms 
of concentration, ratios, constituents, and some CBD products may have trace amount of THC. As 
a result, unknown concerns about long-term effects remain unaddressed, especially in vulnerable 
groups such as children, the elderly, and the chronically or terminally ill. For a clearer judgment 
of the potential therapeutic effects, the risks, and also the legality of a cannabis extract, it is 
important to know its exact composition (Hazekamp, 2018). 
 
Regulation and quality assurance for the cannabinoid content and labelling of edible cannabis 
products are generally lacking. A study of cannabis products in US dispensaries found that more 
than 50% of products evaluated had significantly less cannabinoid content than labelled, with some 
products containing negligible amounts of THC. Such products may not produce the desired 
medical benefit. Other products contained significantly more THC than labelled, placing patients 
at risk of experiencing adverse effects. As medical cannabis is recommended for specific health 
conditions, some of which may be serious, regulation and quality assurance are needed (Vandrey 
et al., 2015). 
 
Lastly, participants were asked to rate their perception of the efficacy of cannabis and / or 
cannabinoids in cancer management. Section 4.7.9 shows that cannabis was perceived as effective 
by 22.2% (n=4) of the participants, while just over half of the participants (55.6%, n=10) rated the 
efficacy as neutral. There was one participant (5.6%, n=1) who perceived cannabis as completely 
ineffective and 16.7% (n=3) of participants stated that they did not know whether cannabis was 




The review by Gardiner et al.  (2019) noted that in addition to the support and opposition of 
medicinal cannabis, three studies reported a high proportion of neutrality when participants were 
asked whether medicinal cannabis had any clinical utility. As mentioned previously, six studies 
reported the majority of participants supporting the clinical usefulness of medicinal cannabis. A 
further five studies indicated that participants believed medicinal cannabis to be a viable 
therapeutic option. In contrast, three studies revealed that the majority of participants believed 
medicinal cannabis to have a limited role in their respective fields, while another study reported a 
lack of confidence in the use of cannabis as a treatment option. Within the study by Gardiner et al. 
participants within an undisclosed pooled sample were largely supportive of medicinal cannabis 
and, although not all supported the use of medicinal cannabis, very few rejected its clinical utility. 
A study within the review by Mitchell et al reported that 55% of Canadian hospital pharmacists 
agreed that overall, medicinal cannabis was effective (Gardiner et al., 2019; Mitchell et al., 2016). 
 
5.8 Limitations of the Study 
A series of limitations may have influenced the outcome of the study. It is noted that most 
participants were from Gauteng (88.9%, n=16), with only n=2 (11.1%) from KwaZulu Natal and 
n=0 from any other regions in South Africa, this limited the study as the data does not depict 
oncologists’ opinions on a national scale. A wider geographical distribution could possibly have 
added different perspectives on the research topic. In addition, the COVID-19 restrictions 
restricted data collection, which may have contributed to the small sample size, and possibly 
decreased the reliability and validity of some of the data collected. A statistical analysis was not 
conducted which could have further elaborated on specific data sets. In terms of the study itself, 
most of the questions in the questionnaire were closed ended which prevented participants from 
explaining their choice or giving context to their answers. There were a few biases which may 
have limited the study, namely, there may be pre-existing bias in the medical profession towards 
homeopaths, and there may be pre-existing bias around the topic of the use of medicinal cannabis 
and cannabinoids. Despite approval of the questionnaire by the HDC (Appendix D) and REC 
(Appendix E), and a small pilot study to assess the questionnaire for bias and ambiguity of 
questions, 13 oncologists would not complete the questionnaire as they perceived the questions to 
be biased.  
 
5.9 Delimitations of the Study 
There were several factors which may have negatively influenced the study: 




• Participants may have a negative perception of cannabis and cannabinoids and therefore chose 
not to participate in the study; 
• Participants have time constraints that prevent them from participating; and  




CHAPTER SIX: CONCLUSIONS AND RECOMMENDATIONS 
 
6.1 Conclusions 
Cancer is the world’s second leading cause of death and reportedly directly affects 1 in 3 people. 
While chemotherapy, radiation and surgery are common treatments for cancer, many patients turn 
to medicinal cannabis and cannabinoids for relief from cancer symptoms and treatment side-
effects.  
 
The objective of this study was to capture, assess, compare, and review South African oncologists’ 
knowledge, perception and recommendation of cannabis and cannabinoids in cancer treatment. 
After analyses of the results, it can be concluded that the majority of participants found value in 
the use of cannabis and cannabinoids in cancer management and chemotherapy or radiation side-
effects. This is despite the almost even response in support for or against the therapeutic use of 
cannabis and cannabinoids. Participants reasoned that the current legal status, lack of supportive 
literature, and perceived ineffectiveness are barriers to the support and use of cannabis in cancer 
management. 
 
Where South African legislation is concerned, the study found that most participants were aware 
of the current status of cannabis with regards to its permissibility for therapeutic use, personal use, 
or practitioner use. However medical professionals could benefit from a publication consisting of 
legal boundaries, SAHPRA recommendations for dosage and purchases and administration forms, 
from which to advise patients.  
 
The study found that more than half the participants were familiar with the common understanding 
of cannabis, its active constituents, and dependence-forming properties, as well as international 
guidelines surrounding the prescription of cannabis. Sources such as websites, journals and clinical 
trials formed the basis of ascertaining knowledge. There is still scope for further education and 
training, since 94.4% (n=17) of participants believed that medical professionals should undergo 
further education prior to being authorized to prescribe cannabis to patients. This is consistent with 
the findings of other studies on a global level. 
 
A specific highlight of the study was the support for the use of cannabis and cannabinoids in 
palliation or advanced stages of cancer in a large range of different cancers, including carcinomas, 
sarcomas, leukaemia, lymphomas, myelomas and brain and spinal cord cancers. Participants also 
perceived that there is value in the use of cannabis and cannabinoids in relieving symptoms of 
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pain, anorexia, nausea, vomiting and insomnia. This may benefit patients who are at the palliation 
or advanced stage of their cancer diagnosis where other medical interventions have failed or are 
considered high-risk. 
 
When questioned who should be allowed to prescribe cannabis to patients, almost two thirds of 
the participants believed that all registered medical doctors should be permitted to do so. Where 
AHPCSA registered practitioners were concerned, the support was lacking. Homeopaths and 
Naturopaths were selected in some instances, however the majority selected either ‘none of the 
above’ or ‘I don’t know’. This may speak to lack of knowledge and understanding that South 
African oncologists have of allied health practitioners and their scope of practice. As stated in 
Chapter 5, the use of cannabis is an integral part of the traditional armamentarium of various CM 
modalities and various preparations may be used for medicinal purposes within the scope of 
Homeopathy, Naturopathy, and other Allied Health Professions.  
 
A strong finding in the study was that participants supported the use of cannabis as an adjunct to 
their treatment and would prescribe cannabis for a host of symptoms including pain, anorexia, 
nausea, insomnia, cachexia, and general wellbeing. Most oncologists in the study remained 
impartial to their patients’ choice to use cannabis and it was established that patient-lead 
conversations surrounding the use of cannabis was growing, while oncologists-initiated 
conversations regarding cannabis usage occurred less often. There is a growing interest amongst 
cancer patients for adjuncts and alternatives to cancer treatment, which allows the patient to make 
informed decisions pertaining to their health 
 
Oncologists in this study favoured CBD, especially as a cannabis oil extract, over other forms of 
cannabis and cannabinoids when discussing or recommending cannabinoid therapies with their 
patients. This speaks to the non-psychoactive properties of CBD, which allows patients to benefit 
from the therapeutic properties of CBD without the cognitive impairment associated with THC. 
Registered oil extracts also provide medical professionals with reputable products with known 
ingredients and formulas that can be incorporated into cancer management. All the participants 
noted that they do not have or use a guideline in prescribing cannabis. This may be owing to the 
fact that the dosage may be altered based on the severity of symptoms, the patient’s age, 
concomitant medication use, and other factors that may differ between patients. The recommended 
dosage may also be influenced by the brand or strength of cannabis or CBD product used. 





The study found that more than half the oncologists deemed cannabis to be effective or to have 
neutral efficacy.  
 
6.2 Recommendations and Limitations 
The following limitations of the study are hereby acknowledged: 
• Most participants were from Gauteng (88.9%, n=16), with only n=2 (11.1%) from 
KwaZulu Natal and n=0 from any other regions in South Africa. A wider geographical 
distribution could possibly have added different perspectives on the research topic. 
• The COVID-19 restrictions restricted data collection, which may have contributed to the 
small sample size.  The small sample size may have decreased the reliability and validity 
of some of the data collected.   
• Most of the questions in the questionnaire were closed ended which prevented participants 
from explaining their choice or giving context to their answers.  
• There may be pre-existing bias in the medical profession against homeopaths. 
• There may be pre-existing bias around the topic of the use of medicinal cannabis and 
cannabinoids. 
• Despite approval of the questionnaire by the HDC (Appendix D) and REC (Appendix E), 
and a small pilot study to assess the questionnaire for bias and ambiguity of questions, 13 




The following are recommendations for future studies: 
• Formulate the study as an interview to allow for expansion of questions and a broader 
collection of data. 
• Conduct the research at conventions or meetings to allow for maximum participation. 
• Focus specifically on one key component of the study, rather than a brief overview of 
knowledge, perception, prescription, and legalisation. 
• Investigate the knowledge, attitudes and practices related to medical cannabis of other 
practitioners that manage cancer patients, such as palliative care practitioners, hospice 
staff, pharmacists etc. 
• Investigate the knowledge, attitudes and practices related to medical cannabis within the 
scope of Homeopathy, Phytotherapy and other allied health professions. 
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• Offer CPD points via the HPCSA for completion of the survey to incentivise participants. 
• Focus on a particular type of cancer and modify the questions and symptoms to attain a 
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APPENDIX A: Information Letter 
 
 





DEPARTMENT OF HOMEOPATHY 






My name is Zahraa Kazee I WOULD LIKE TO INVITE YOU TO PARTICIPATE in a 
research study on in a research study to explore oncologists’ knowledge and recommendation of 
cannabis and cannabinoids in cancer management. 
 
Before you decide on whether to participate, please read the information below. This should take 
about 10-15 minutes. The study is part of a research project being completed as a requirement for 
a Master’s Degree in Homeopathy (M Tech Hom) through the University of Johannesburg. 
 
THE PURPOSE OF THIS STUDY is to gather input from oncologists regarding their 
knowledge, perceptions, recommendation and understanding of cannabis use amongst their 
patients for therapeutic purposes. This study may be able to establish gaps in the education 
(including the ongoing education) of oncologists. 
 
Below, I have compiled a set of questions and answers that I believe will assist you in 
understanding the relevant details of participation in this research study. Please read through these. 
If you have any further questions, I will be happy to answer them for you. 
 
DO I HAVE TO TAKE PART? No, you don’t have to. It is entirely your decision to participate 






WHAT EXACTLY WILL I BE EXPECTED TO DO IF I AGREE TO PARTICIPATE? 
Once you have consented to participation, you will be provided with a link to a Google Docs form. 
The form is divided into Sections A-F. Please complete all sections. Once you have completed 
Section E you will then submit the completed form. None of your personal information will be 
requested in this study and the survey submission has no trace back to the original email link. 
 
WHAT WILL HAPPEN IF I WANT TO WITHDRAW FROM THE STUDY? You may 
withdraw from the study at any time up until your final submission of the survey. Should you wish 
to withdraw, please do not submit the form. Once the form is submitted online, the completed 
survey cannot be withdrawn, as all submissions are anonymous, and your submission cannot be 
linked back to you.  
 
IF I CHOOSE TO PARTICIPATE, WILL THERE BE ANY EXPENSES FOR ME, OR 
PAYMENT DUE TO ME: You will not be paid to participate in this study and you will not bear 
any expenses.  
 
RISKS INVOLVED IN PARTICIPATION: There are no risks anticipated for this study. 
 
BENEFITS INVOLVED IN PARTICIPATION: There is no direct benefits to you, however, 
you will create insight into the use and value of cannabis and cannabinoids through your 
participation by shedding light on the matter with practitioner experience. You will also assist in 
guiding tertiary education on the topic of cannabinoid usage. This study will provide the 
groundwork for further education, legislation and research in South Africa   
 
WILL MY PARTICIPATION IN THIS STUDY BE KEPT CONFIDENTIAL? Yes, 
participation will be both confidential as well as anonymous in this study. The researcher will have 
access to participants’ email addresses, however there will be no link between the submission and 
the email from which it was submitted from thus ensuring confidentiality of each participant.  
No names or identifying factors will be associated with the survey submissions. In this way 





WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY? The results 
will be written into a research report that will be assessed. The results may also be published in a 
scientific journal. In either case, you will not be identifiable in any documents, reports or 
publications. You will be given access to the study results if you would like to see them, by 
contacting me. 
 
WHO IS ORGANISING AND FUNDING THE STUDY?  The study is being organized by me, 
under the guidance of my research supervisor at the Department of Homeopathy in the University 
of Johannesburg. The University has provided limited funding for this study. 
 
WHO HAS REVIEWED AND APPROVED THIS STUDY? Before this study was allowed to 
start, it was reviewed in order to protect your interests. This review was done first by the 
Department of Homeopathy, and then secondly by the Higher Degrees Committee and lastly by 
the Faculty of Health Sciences Research Ethics Committee at the University of Johannesburg. In 
all three cases, the study was approved. 
 
WHAT IF THERE IS A PROBLEM? If you have any concerns or complaints about this research 
study, its procedures or risks and benefits, please don’t hesitate to contact me or my research 
supervisor. You should contact me at any time if you feel you have any concerns about being a 
part of this study. 
 
My contact details are: 
Zahraa Kazee 
074 786 1313 
zarakazee@gmail.com 
You may also contact my research 
supervisor: 
Dr. Marelize Caminsky (Bekker) 
mcaminsky@uj.ac.za
 
If you feel that any questions or complaints regarding your participation in this study have not 
been dealt with adequately, you may contact the Chairperson of the Faculty of Health Sciences 
Research Ethics Committee at the University of Johannesburg: 
 
Prof. Chris Stein 





FURTHER INFORMATION AND CONTACT DETAILS: Should you wish to have more 
specific information about this research project, have any questions, concerns or complaints about 
this research study, its procedures, risks and benefits, you may communicate with me using any of 




















DEPARTMENT OF HOMEOPATHY 
RESEARCH CONSENT FORM 
 
A survey to explore and describe South African oncologists’ knowledge and recommendation of 
cannabis and cannabinoids for cancer management 
 
Please initial each box below: 
 
I confirm that I have read and understand the information letter dated January 2020 
or the above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
I understand that my participation is voluntary and that I am free to withdraw from 
this study at any time without giving any reason and without any consequences to me. 
 
I agree to take part in the above study. 
 
 
_________________                    _____________________           __________________ 
Name of Participant        Signature of Participant  Date 
 
_________________                    _____________________           __________________ 
 




APPENDIX C: Questionnaire 
Oncologists’ perceptions and recommendation of cannabis and cannabinoids in cancer 
management. 
 















 Free State 
 Eastern Cape 
 Mpumalanga 
 Northern Cape 
 North West 
 Western Cape 
 










Section B – Perception on the use of cannabis  









I do not know  
 
 
C) Do you see value in the therapeutic / medicinal use of cannabis and cannabinoid in the 
management of chemotherapy/radiation side effects? 
Yes  
No  
I do not know  
 
2. If you answered NO, to any of the above questions, kindly indicate why you do not support 
the therapeutic / medicinal use of cannabis and cannabinoids. Mark all applicable: 
Due to the side effects of cannabinoids  
Cannabis and Cannabinoids do not work  
Lack of research or literature to support it  
Personal lack of knowledge  
Other medication is more effective  
Religious/ Moral beliefs  
Current legalization status  








Section C – Legalization       
 




 I do not know 
 
2. Cannabis is legal in South Africa as long as people use it only in their own homes. 
 Yes 
 No 
 I do not know 
 
3. I am currently permitted to apply to the Director General of Health to prescribe cannabis 
for therapeutic purposes for a patient. 
 Yes 
 No 



















Section D – Knowledge       
1. Cannabis & Cannabinoids are different substances? 
 Yes 
 No 
 I do not know 
 
2. I am familiar with the research and international regulations regarding approved 
cannabinoids in managing cancer symptoms and treatment side effects? 
 Yes 
 No 
 I do not know 
 
3. If you answered yes to the above (Q2), kindly indicate what sources you use to obtain this 
information: Mark all applicable 
 Social media 
 Conferences 
 Internet & websites 
 Journals 
 Evidence based research & clinical trials 
 From speaking to colleagues 
 A medical professional body/ association 
  Other: ______________________________________________________ 
 
4. Please select one or more statement that best describes the dependence forming potential 
of cannabis: 
 I don't know whether cannabis is addictive or how addictive it may or may not 
be 
 Cannabis is a highly addictive substance like opiate drugs and medicines 
 Cannabis is more addictive than alcohol and tobacco, but not as addictive as 
opiate drugs and medicines. 
 Cannabis is less addictive than alcohol and tobacco 





Section E – Recommendation and Perceived Value 
 
1. Kindly indicate which of the following symptoms you think cannabinoids may relieve: 














2. At what stages of the disease would you consider the therapeutic / medicinal use of 
cannabinoids in cancer management: Mark all applicable 
 All stages 
 Early 
 Localised & non-invasive 
 Localised & invasive 
 Advanced 
 Palliation 
 None of the above 
 




 Lymphomas  
 Myelomas 




 None of the above 
 
 
Section F- Prescription 
 
1. In the event that the therapeutic / medicinal use of cannabis become less restricted, should 
those practitioners that are allowed to prescribe cannabis be required to first complete a 
clinical training course on the human endocannabinoid system and prescribing cannabis-
based medicines as part of their degree or as a post graduate course? 
Yes                                                No  
 
 
2. If the therapeutic / medicinal use of cannabis become less restricted, which Health 
Professions Council (HPCSA) practitioner(s) should be allowed to prescribe cannabis to 
patients? Mark all applicable: 
 Oncologists only 
 All medical doctors 
 Advanced nursing practitioners, not all nurses 
 All nurses, not only advanced nursing practitioners 
 Clinical pharmacists, not all pharmacists 
 All pharmacists, not just clinical pharmacists 
 Dentists 
 Physiotherapists 
 None of the above 










3. Should the therapeutic use of cannabis become less restricted, which Allied Health 
Professions Council (AHPCSA) practitioner(s) should be allowed to prescribe cannabis to 
patients? Mark all applicable: 
 Homeopaths 
 Naturopaths 
 Phytotherapists (herbal practitioners) 
 Chiropractors 
 Osteopaths 
 Practitioners of Traditional Chinese Medicine (TCM) 
 Practitioners of Unani Tibb 
 Practitioners of Ayurveda 
 None of the above 
 All practitioners registered with AHPCSA    
 I do not know 
 
4. Do you currently recommend or prescribe cannabis or cannabinoids as an adjunct to cancer 
treatment? 
Yes                                                No  
 
5. Please specify which symptoms you would recommend or prescribe cannabis or  




















6. If your patient informs you that they are independently using cannabis as an adjunct to your 
treatment plan, what is your current response?  
 I express absolute support for their choice  
 I express support for their choice, but caution them  
  I tell them that I am not for it, nor am I against it. They can choose for 
themselves. 
  I advise them against using cannabis but will continue treating them despite 
the fact that they choose to use it. 
  I advise them against using cannabis and refuse to continue treating them if 
they decide to continue using cannabis 
 
7. Please select one option below that best describes your experience in practice? 
 Patients discuss an interest in using cannabis therapeutically with me 
on a daily basis 
 Patients discuss an interest in using cannabis therapeutically with me 
several times a week 
 Patients discuss an interest in using cannabis therapeutically with me 
several times a month 
 Patients discuss an interest in using cannabis therapeutically with me 
approximately once a month 
 Patients discuss an interest in using cannabis therapeutically with me 
once every 2 - 6 months 
 No Patients has never discussed an interest in using cannabis 
therapeutically 
 
8. Please select one option below that best describes your approach in practice? 
 I initiate a conversation regarding cannabis use with all patients 
 I initiate a conversation regarding cannabis use with some of my 
patients 






9. Which cannabis or cannabinoid would you recommend or use? Mark all applicable: 
 Cannabis plant 
 Synthetic THC (for example Marinol or Cesamet) 
 CBD 
 Other: ___________________________________ 
 
10 What administration form would you recommend or use if a patient wants to use a plant-
based cannabis medicine? Mark all applicable:  
 Registered cannabis oil extracts such as Sativex and Epiliolex  
 Cannabis tea or other edible preparations 
 Smoked  
 Vaporized 
 Suppository  
 Topical applications such as creams or lotions 
 Cannabis oil extracts that have not been registered 
 I would not recommend any plant-based cannabis treatments - I will only 
recommend synthetic cannabinoids such as Marinol & Cesamet 
 I would never recommend cannabis-based medicines, whether synthetic or-




10.  Is there a guideline or criteria you follow to determine the use of cannabinoids in cancer? 
Yes                                                No  
 











12. How would you rate the efficacy of cannabis in cancer management? 




 Completely ineffective  
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